

    <!DOCTYPE html>
<html class="">

        
<head>
    <title>Recent advances in the understanding and... | F1000Research</title>
    <meta charset="utf-8">
    <!--<meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>-->
    <!--<meta lang="$locale">-->
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="google-site-verification" content="9-QVycOO2_ob3Z9QzRmXv2CF08A9oyYXqWyTiVdKPlU" />
    <!-- This is commented out to fix display problems on mobile devices.
    We may use it again once we implement a responsive design that supports native device resolutions.
    <meta name="viewport" content="width=device-width"> -->

    <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1">



    <link rel="alternate" title="Recent articles published in F1000Research" href="/rss" type="application/rss+xml">
            <link rel="alternate" type="application/pdf" title="PDF" href="https://f1000research.com/articles/8-1961/pdf"/>
        <link rel="canonical" href="https://f1000research.com/articles/8-1961" />
    
            <meta name="description" content="Read the original article in full on F1000Research: Recent advances in the understanding and therapeutic management of mastocytosis" />
    
            <meta name="og:title" content="F1000Research Article: Recent advances in the understanding and therapeutic management of mastocytosis.">
            <meta name="og:description" content="Read the latest article version by Julien Rossignol, Laura Polivka, Leila Maouche-Chr&eacute;tien, Laurent Frenzel, Patrice Dubreuil, Olivier Hermine, at F1000Research.">
            <meta name="og:image" content="/img/sharing/og_research.png">
            <meta name="version-id" content="21341">
            <meta name="article-id" content="19463">
            <meta name="dc.title" content="Recent advances in the understanding and therapeutic management of mastocytosis">
            <meta name="dc.description" content="Mastocytosis is a rare disease due to the abnormal accumulation of mast cells in various tissues. Its clinical presentation is heterogeneous depending on mast cell infiltration and mediators release. In some cases, it is associated with hematological malignancies. Prognosis varies from very good with a life expectancy similar to the general population in indolent forms of the disease to a survival time of just a few months in mast cell leukemia. Although in most cases a somatic KIT D816V mutation is found in tumor mast cells, the physiopathology of the disease is not yet fully understood. Additional germline and somatic mutations may explain this heterogeneity. Treatments aim at blocking effect of mast cell mediators, reducing mast cell activation and tumor burden. New drugs mainly directed against the tyrosine kinase activity of KIT have dramatically changed the quality of life and prognosis of mast cell diseases. Present and future therapeutic strategies are discussed in this review.">
            <meta name="dc.subject" content="Mastocytosis, physiopathology, treatment, management, leukemia, mast cell ">
            <meta name="dc.creator" content="Rossignol, Julien">
            <meta name="dc.creator" content="Polivka, Laura">
            <meta name="dc.creator" content="Maouche-Chr&eacute;tien, Leila">
            <meta name="dc.creator" content="Frenzel, Laurent">
            <meta name="dc.creator" content="Dubreuil, Patrice">
            <meta name="dc.creator" content="Hermine, Olivier">
            <meta name="dc.date" content="2019/11/22">
            <meta name="dc.identifier" content="doi:10.12688/f1000research.19463.1">
            <meta name="dc.source" content="F1000Research 2019 8:1961">
            <meta name="dc.format" content="text/html">
            <meta name="dc.language" content="en">
            <meta name="dc.publisher" content="F1000 Research Limited">
            <meta name="dc.rights" content="https://creativecommons.org/licenses/by/3.0/igo/">
            <meta name="dc.type" content="text">
            <meta name="prism.keyword" content="Mastocytosis">
            <meta name="prism.keyword" content="physiopathology">
            <meta name="prism.keyword" content="treatment">
            <meta name="prism.keyword" content="management">
            <meta name="prism.keyword" content="leukemia">
            <meta name="prism.keyword" content="mast cell ">
            <meta name="prism.publication.Name" content="F1000Research">
            <meta name="prism.publicationDate" content="2019/11/22">
            <meta name="prism.volume" content="8">
            <meta name="prism.number" content="1961">
            <meta name="prism.versionIdentifier" content="1">
            <meta name="prism.doi" content="10.12688/f1000research.19463.1">
            <meta name="prism.url" content="https://f1000research.com/articles/8-1961">
            <meta name="citation_title" content="Recent advances in the understanding and therapeutic management of mastocytosis">
            <meta name="citation_abstract" content="Mastocytosis is a rare disease due to the abnormal accumulation of mast cells in various tissues. Its clinical presentation is heterogeneous depending on mast cell infiltration and mediators release. In some cases, it is associated with hematological malignancies. Prognosis varies from very good with a life expectancy similar to the general population in indolent forms of the disease to a survival time of just a few months in mast cell leukemia. Although in most cases a somatic KIT D816V mutation is found in tumor mast cells, the physiopathology of the disease is not yet fully understood. Additional germline and somatic mutations may explain this heterogeneity. Treatments aim at blocking effect of mast cell mediators, reducing mast cell activation and tumor burden. New drugs mainly directed against the tyrosine kinase activity of KIT have dramatically changed the quality of life and prognosis of mast cell diseases. Present and future therapeutic strategies are discussed in this review.">
            <meta name="citation_description" content="Mastocytosis is a rare disease due to the abnormal accumulation of mast cells in various tissues. Its clinical presentation is heterogeneous depending on mast cell infiltration and mediators release. In some cases, it is associated with hematological malignancies. Prognosis varies from very good with a life expectancy similar to the general population in indolent forms of the disease to a survival time of just a few months in mast cell leukemia. Although in most cases a somatic KIT D816V mutation is found in tumor mast cells, the physiopathology of the disease is not yet fully understood. Additional germline and somatic mutations may explain this heterogeneity. Treatments aim at blocking effect of mast cell mediators, reducing mast cell activation and tumor burden. New drugs mainly directed against the tyrosine kinase activity of KIT have dramatically changed the quality of life and prognosis of mast cell diseases. Present and future therapeutic strategies are discussed in this review.">
            <meta name="citation_keywords" content="Mastocytosis, physiopathology, treatment, management, leukemia, mast cell ">
            <meta name="citation_journal_title" content="F1000Research">
            <meta name="citation_author" content="Julien Rossignol">
            <meta name="citation_author_institution" content="Department of Hematology, Gustave Roussy Institute, Paris-Saclay University, Villejuif, France">
            <meta name="citation_author_institution" content="French Reference Center for Mastocytosis (CEREMAST), Necker Children's Hospital, APHP, Paris, France">
            <meta name="citation_author_institution" content="Imagine Institute, Paris University, INSERM U 1183, Paris, France">
            <meta name="citation_author" content="Laura Polivka">
            <meta name="citation_author_institution" content="Centre de Recherche en Canc&eacute;rologie de Marseille, Inserm U1068, Marseille, France">
            <meta name="citation_author_institution" content="French Reference Center for Mastocytosis (CEREMAST), Necker Children's Hospital, APHP, Paris, France">
            <meta name="citation_author_institution" content="Imagine Institute, Paris University, INSERM U 1183, Paris, France">
            <meta name="citation_author" content="Leila Maouche-Chr&eacute;tien">
            <meta name="citation_author_institution" content="Imagine Institute, Paris University, INSERM U 1183, Paris, France">
            <meta name="citation_author_institution" content="French Reference Center for Mastocytosis (CEREMAST), Necker Children's Hospital, APHP, Paris, France">
            <meta name="citation_author" content="Laurent Frenzel">
            <meta name="citation_author_institution" content="French Reference Center for Mastocytosis (CEREMAST), Necker Children's Hospital, APHP, Paris, France">
            <meta name="citation_author_institution" content="Imagine Institute, Paris University, INSERM U 1183, Paris, France">
            <meta name="citation_author_institution" content="Department of Hematology, Necker Children's Hospital, APHP, Paris, France">
            <meta name="citation_author" content="Patrice Dubreuil">
            <meta name="citation_author_institution" content="Department of Dermatology, Necker Children's Hospital, APHP, Paris, France">
            <meta name="citation_author_institution" content="French Reference Center for Mastocytosis (CEREMAST), Necker Children's Hospital, APHP, Paris, France">
            <meta name="citation_author" content="Olivier Hermine">
            <meta name="citation_author_institution" content="French Reference Center for Mastocytosis (CEREMAST), Necker Children's Hospital, APHP, Paris, France">
            <meta name="citation_author_institution" content="Imagine Institute, Paris University, INSERM U 1183, Paris, France">
            <meta name="citation_author_institution" content="Department of Hematology, Necker Children's Hospital, APHP, Paris, France">
            <meta name="citation_publication_date" content="2019/11/22">
            <meta name="citation_volume" content="8">
            <meta name="citation_publication_number" content="1961">
            <meta name="citation_version_number" content="1">
            <meta name="citation_doi" content="10.12688/f1000research.19463.1">
            <meta name="citation_firstpage" content="1961">
            <meta name="citation_pdf_url" content="https://f1000research.com/articles/8-1961/v1/pdf">
    

    
    <link href="/img/favicon-research.ico" rel="shortcut icon" type="image/ico">
    <link href="/img/favicon-research.ico" rel="icon" type="image/ico">

        <link rel="stylesheet" href="/1597255280893/css/mdl/material-design-lite.css" type="text/css" media="all" />
    <link href="https://fonts.googleapis.com/icon?family=Material+Icons" rel="stylesheet">
    <link href="https://fonts.googleapis.com/css?family=Roboto:100,100i,300,300i,400,400i,500,500i,700,700i,900,900i" rel="stylesheet">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/MaterialDesign-Webfont/2.2.43/css/materialdesignicons.min.css" />

        
            
    <link rel="stylesheet" href="/1597255280893/css/F1000Research.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/animation.css" type="text/css" media="all" />

        <!--[if IE 7]><link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons-ie7.css" media="all" /><![endif]-->

                    <script>dataLayer = [];</script>
        <!-- Google Tag Manager -->
        <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
        new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
        j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
        'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
        })(window,document,'script','dataLayer','GTM-54Z2SBK');</script>
        <!-- End Google Tag Manager -->
    
    <script src="https://ajax.googleapis.com/ajax/libs/jquery/1.8.1/jquery.min.js"></script>
    <script>window.jQuery || document.write('<script src="/js/vendor/jquery-1.8.1.min.js"><\/script>')</script>
    <script src="/1597255280893/js/vendor/modernizr-2.6.1-respond-1.1.0.min.js"></script>
    <script src="/1597255280893/js/shared_scripts/sticky.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/shared_scripts/menu.js"></script>
    <script src="/1597255280893/js/shared_scripts/navbar.js"></script>
    <script src="/1597255280893/js/shared_scripts/platforms.js"></script>
    <script src="/1597255280893/js/shared_scripts/object-polyfills.js"></script>
            <script src="/1597255280893/js/vendor/lodash.min.js"></script>
        <script>CKEDITOR_BASEPATH='https://f1000research.com/js/ckeditor/'</script>
    <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/plugins.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/app/research.js"></script>
    <script>window.reactTheme = 'research';</script>
    <script src="/1597255280893/js/public/bundle.js"></script>

    <script src="/1597255280893/js/app/research.ui.js"></script>
    <script src="/1597255280893/js/app/login.js"></script>
    <script src="/1597255280893/js/app/main.js"></script>
    <script src="/1597255280893/js/app/js-date-format.min.js"></script>
    <script src="/1597255280893/js/app/search.js"></script>
    <script src="/1597255280893/js/app/cookies_warning.js"></script>
    <script src="/1597255280893/js/mdl/mdl.min.js"></script>

    <script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>
                <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/ckeditor.js"></script>
            <script src="/js/ckeditor/adapters/jquery.js"></script>
                <script src="/js/article/article_scrolling_module.js"></script>
            <script src="/js/article/article_stats.js"></script>
            <script src="/js/article/article.js"></script>
            <script src="/js/shared_scripts/referee_timeline_pagination.js"></script>
            <script src="/js/app/text_editor_controller.js"></script>
            <script src="//s7.addthis.com/js/250/addthis_widget.js#pubid=ra-503e5e99593dc42c"></script>
            <script src="/js/article/article_metrics.js"></script>
        
                                                                            <script>
            if (window.location.hash == '#_=_'){
                window.location = window.location.href.split('#')[0]
            }
        </script>

                    
        
    <!-- pixelId: 1641728616063202 :: assetPixelId: 6034867600215 :: funderPixelId:  -->

            <!-- Facebook pixel code (merged with EP GTM code) -->
        <script>
            !function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function()

            {n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)}
            ;if(!f._fbq)f._fbq=n;
            n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0;
            t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window,
            document,'script','https://connect.facebook.net/en_US/fbevents.js');

            fbq('init', '1641728616063202');

            
            fbq('track', "PixelInitialized", {});
        </script>

        <noscript><img height="1" width="1" style="display:none"
            src="https://www.facebook.com/tr?id=1641728616063202&noscript=1&amp;ev=PixelInitialized"
        /></noscript>
        <!-- End Facebook Pixel Code -->
    
                <script>
            (function(h,o,t,j,a,r){
                h.hj=h.hj||function(){(h.hj.q=h.hj.q||[]).push(arguments)};
                h._hjSettings={hjid:917825,hjsv:6};
                a=o.getElementsByTagName('head')[0];
                r=o.createElement('script');r.async=1;
                r.src=t+h._hjSettings.hjid+j+h._hjSettings.hjsv;
                a.appendChild(r);
            })(window,document,'https://static.hotjar.com/c/hotjar-','.js?sv=');
        </script>
    
</head>
<body  class="o-page-container no-js p-article o-layout-reset   ">

    
                            <!-- Google Tag Manager (noscript) -->
        <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-54Z2SBK"
        height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
        <!-- End Google Tag Manager (noscript) -->
    
        
    <div class="o-page">

        <div id="notify-container"></div>
        <div id="pageWarning"></div>
        <div id="pageMessage"></div>
        <div id="pageFooterMessage"></div>

                                <div id="f1r-ga-data" data-name="f1r-ga-data" class="f1r-ga-data"
                data-user-registered="false"
                data-user-module=""
                data-current-path=""
                data-location=""
                data-website="F1000Research"
                data-websiteDisplayName="F1000Research">
            </div>
        
                
        
        <div class="header-wrapper   js-navbar-space ">
                            


    










        
                            
    
            



<nav class="c-navbar js-navbar js-mini-nav js-sticky c-navbar--js-sticky c-navbar--userSite c-navbar__platform-bgcolor  c-navbar--bg-f1000research ">

    <div class="c-navbar__content">

                                <div class="c-navbar__extras">
            <div class="o-wrapper">
                <div class="o-actions o-actions--middle c-navbar__extras-row">
                    <div class="o-actions__primary">
                        
                                            </div>
                                    </div>
            </div>
        </div>

        <div class="o-wrapper t-inverted js-sticky-start">

            <div class="c-navbar__branding-row">
                <div class="c-navbar__row">


                                        
                    <div class="c-navbar__primary u-mr--2">

                                                                                                                                                                                                    <a href="/" class="c-navbar__branding u-ib u-middle"   data-test-id="nav_branding"  >
                                <img class="u-ib u-middle" src="/img/research/F1000Research_white_solid.svg" alt="F1000Research">
                            </a>
                                            </div>

                    <div class="c-navbar__secondary c-navbar__row">


                                                
                                                    <form action="/search" class="-navbar__secondary u-mr--2 c-search-form js-search-form u-hide u-show@navbar">
                                <label for="searchInput" class="c-search-form__label _mdl-layout">
                                    <input name="q" type="search" class="c-search-form__input" id="searchInput" placeholder="Search">
                                    <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                </label>
                            </form>
                        
                                                
                                                    <div class="c-navbar__primary u-hide u-show@navbar">
                                <div class="_mdl-layout c-navbar__cta">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--no-shadow mdl-button--multi-line mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                            </div>
                        

                                                
                        <span class="u-hide@navbar _mdl-layout u-nowrap">

                                                            <button type="button" class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" data-focus="#navbar_mob_search_input" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_search_mob"  ><i class="material-icons">search</i></button>
                            
                                                            <button class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon mdl-button--multi-line c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" type="button" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_toggle_mob"  >
                                    <i class="material-icons c-navbar__toggle-open">menu</i>
                                    <i class="material-icons c-navbar__toggle-close">close</i>
                                </button>
                                                    </span>
                    </div>

                </div>
            </div>

                        
                            <div class="c-navbar__menu-row js-navbar-block is-collapsed" id="navbarMenu">

                                                                                                                                                
                                                                    
                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                            

                                                                
                                                                                                                                                                                                                                
                                            
                    <div class="c-navbar__menu-row-content">

                                                                            <div class="u-hide@navbar c-navbar__menu-bar-spacing">
                                <form action="/search" class="c-search-form js-search-form">
                                    <label for="navbar_mob_search_input" class="c-search-form__label _mdl-layout">
                                        <input id="navbar_mob_search_input" name="q" type="search" class="c-search-form__input" placeholder="Search">
                                        <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                    </label>
                                </form>
                            </div>
                        
                        <div class="o-actions o-actions--middle">

                            <div class="o-actions__primary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="main-menu"   role="menubar" aria-label="Main Navigation"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/browse/articles" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="0"
                              data-test-id="nav_browse"                              >Browse</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/gateways" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_gatewaysViewAndBrowse"                              >Gateways & Collections</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="2"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_for-authors"                              >How to Publish</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="How to Publish">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_submit-manuscript"                      href="/for-authors/publish-your-research"
                    role="menuitem"
                    tabindex="0">Submit your Research</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/for-authors/my-submissions"
                    role="menuitem"
                    tabindex="-1">My Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines"                      href="/for-authors/article-guidelines"
                    role="menuitem"
                    tabindex="-1">Article Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines-new-versions"                      href="/for-authors/article-guidelines-new-versions"
                    role="menuitem"
                    tabindex="-1">Article Guidelines (New Versions)</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_data-guidelines"                      href="/for-authors/data-guidelines"
                    role="menuitem"
                    tabindex="-1">Data Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_asset-guidelines"                      href="/for-authors/posters-and-slides-guidelines"
                    role="menuitem"
                    tabindex="-1">Posters and Slides Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_document-guidelines"                      href="/for-authors/document-guidelines"
                    role="menuitem"
                    tabindex="-1">Document Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-processing-charges"                      href="/for-authors/article-processing-charges"
                    role="menuitem"
                    tabindex="-1">Article Processing Charges</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_finding-referees"                      href="/for-authors/tips-for-finding-referees"
                    role="menuitem"
                    tabindex="-1">Finding Article Reviewers</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="3"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_about-contact"                              >About</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="About">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_about-page"                      href="/about"
                    role="menuitem"
                    tabindex="0">How it Works</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_referee-guidelines"                      href="/for-referees/guidelines"
                    role="menuitem"
                    tabindex="-1">For Reviewers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_advisoryPanel"                      href="/advisors"
                    role="menuitem"
                    tabindex="-1">Our Advisors</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_policy-page"                      href="/about/policies"
                    role="menuitem"
                    tabindex="-1">Policies</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_glossary-page"                      href="/glossary"
                    role="menuitem"
                    tabindex="-1">Glossary</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_faqs-page"                      href="/faqs"
                    role="menuitem"
                    tabindex="-1">FAQs</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              u-hide u-show@navbar"
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      u-hide u-show@navbar"
                                          data-test-id="nav_for-developers"                      href="/developers"
                    role="menuitem"
                    tabindex="-1">For Developers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_newsroom-page"                      href="/newsroom"
                    role="menuitem"
                    tabindex="-1">Newsroom</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_contact-page"                      href="/contact"
                    role="menuitem"
                    tabindex="-1">Contact</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="4"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="https://blog.f1000.com/blogs/f1000research/" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                             target="_blank"                                                         tabindex="-1"
                              data-test-id="nav_blog"                              >Blog</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                            <div class="o-actions__secondary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="secondary-items"   role="menubar" aria-label="My Account"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="0"
                              data-test-id="nav_my-research"                              >My Research</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="My Research">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/login?originalPath=/my/submissions"
                    role="menuitem"
                    tabindex="0">Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-email-alerts"                      href="/login?originalPath=/my/email-alerts"
                    role="menuitem"
                    tabindex="-1">Content and Tracking Alerts</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-user-details"                      href="/login?originalPath=/my/user-details"
                    role="menuitem"
                    tabindex="-1">My Details</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/login?originalPath=/articles/8-1961.html" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_sign-in"                              >Sign In</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                                                                                        <div class="_mdl-layout c-navbar__cta u-hide@navbar c-navbar__menu-bar-spacing">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--multi-line mdl-button--no-shadow mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research_mob"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                                                    </div>

                    </div>

                </div>
            
        </div>

    </div>

</nav>
                    </div>

        <div class="content-wrapper o-page__main row ">
            <div id="highlight-area" class="content ">
                





<div id=article-metadata class=hidden> <input type=hidden name=versionId value=21341 /> <input type=hidden id=articleId name=articleId value=19463 /> <input type=hidden id=xmlUrl value="/articles/8-1961/v1/xml"/> <input type=hidden id=xmlFileName value="-8-1961-v1.xml"> <input type=hidden id=article_uuid value=f40c1a70-3292-4db5-9d4a-8543dc0a57d2 /> <input type=hidden id=referer value=""/> <input type=hidden id=meta-article-title value="Recent advances in the understanding and therapeutic management of mastocytosis"/> <input type=hidden id=workspace-export-url value="https://sciwheel.com/work/api/import/external?doi=10.12688/f1000research.19463.1"/> <input type=hidden id=versionDoi value="10.12688/f1000research.19463.1"/> <input type=hidden id=usePmcStats value=true /> </div> <main class="o-wrapper p-article__wrapper js-wrapper"> <script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "ScholarlyArticle",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://f1000research.com/articles/8-1961"
  },
  "headline": "Recent advances in the understanding and therapeutic management of mastocytosis",
  "datePublished": "2019-11-22T17:24:44",
  "dateModified": "2019-11-22T17:24:44",
  "author": [
    {
      "@type": "Person",
      "name": "Julien Rossignol"
    },    {
      "@type": "Person",
      "name": "Laura Polivka"
    },    {
      "@type": "Person",
      "name": "Leila Maouche-Chr&eacute;tien"
    },    {
      "@type": "Person",
      "name": "Laurent Frenzel"
    },    {
      "@type": "Person",
      "name": "Patrice Dubreuil"
    },    {
      "@type": "Person",
      "name": "Olivier Hermine"
    }  ],
  "publisher": {
    "@type": "Organization",
    "name": "F1000Research",
    "logo": {
      "@type": "ImageObject",
      "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
      "height": 480,
      "width": 60
    }
  },
  "image": {
    "@type": "ImageObject",
    "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
    "height": 1200,
    "width": 150
  },
  "description": "Mastocytosis is a rare disease due to the abnormal accumulation of mast cells in various tissues. Its clinical presentation is heterogeneous depending on mast cell infiltration and mediators release. In some cases, it is associated with hematological malignancies. Prognosis varies from very good with a life expectancy similar to the general population in indolent forms of the disease to a survival time of just a few months in mast cell leukemia. Although in most cases a somatic KIT D816V mutation is found in tumor mast cells, the physiopathology of the disease is not yet fully understood. Additional germline and somatic mutations may explain this heterogeneity. Treatments aim at blocking effect of mast cell mediators, reducing mast cell activation and tumor burden. New drugs mainly directed against the tyrosine kinase activity of KIT have dramatically changed the quality of life and prognosis of mast cell diseases. Present and future therapeutic strategies are discussed in this review."
}
</script> <div class="o-layout o-layout--right-gutter"> <div id=article_secondary-column class="p-article__main o-layout__item u-font-size--legal u-2/3@article not-expanded "> <div class=float-left> <script type="application/ld+json">
  {
    "@context": "http://schema.org",
    "@type": "BreadcrumbList",
    "itemListElement": [
              {
          "@type": "ListItem",
          "position": "1",
          "item": {
            "@id": "https://f1000research.com/",
            "name": "Home"
          }
        },              {
          "@type": "ListItem",
          "position": "2",
          "item": {
            "@id": "https://f1000research.com/browse/articles",
            "name": "Browse"
          }
        },              {
          "@type": "ListItem",
          "position": "3",
          "item": {
            "@id": "https://f1000research.com/articles/8-1961/v1",
            "name": "Recent advances in the understanding and therapeutic management of..."
          }
        }          ]
  }
  </script> <div class="breadcrumbs js-breadcrumbs"> <a href="/" class=f1r-standard-link>Home</a> <span class=item_separator></span> <a href="/browse/articles" class=f1r-standard-link>Browse</a> <span class=item_separator></span> Recent advances in the understanding and therapeutic management of... </div> </div> <div class="article-badges-container u-mb--2"> <div class=crossmark-new> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js"></script> <a data-target=crossmark><img height=30 width=150 src="https://crossmark-cdn.crossref.org/widget/v2.0/logos/CROSSMARK_Color_horizontal.svg"/></a> </div> <div id=crossmark-dialog style="display: none;" title=""> <iframe id=crossmark-dialog-frame frameborder=0></iframe> </div> <div class=clearfix></div> </div> <div class=article-interaction-container> <div id=main-article-count-box class=article-count-box> <div class="article-metrics-wrapper metrics-icon-wrapper" data-version-id=21341 data-id=19463 data-downloads="" data-views="" data-scholar="10.12688/f1000research.19463.1" data-recommended="" data-doi="10.12688/f1000research.19463.1" data-f1r-ga-helper="Article Page Metrics (Desktop)"> <span class="metrics-on-browse article-metrics-icon f1r-icon icon-89_metrics"></span> <div class="count-title article-metrics-text">ALL Metrics</div> <div class=js-article-metrics-container></div> </div> <div> <div class=count-delimiter></div> <div title="Total views from F1000Research and PubMed Central"> <div class="count-container view-count js-views-count">-</div> <div class=count-title><span class="count-title-icon count-title-views-icon"></span>Views</div> </div> <div class=download-counts hidden> <div class=count-delimiter></div> <div title="Total downloads from F1000Research and PubMed Central"> <div class="count-container js-downloads-count"></div> <div class=count-title><span class="count-title-icon f1r-icon icon-76_download_file"></span>Downloads</div> </div> </div> </div> </div> <div id=main-article-interaction-box class="article-interaction-box has-control-tab"> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-102_download_pdf"></span> <a href="https://f1000research.com/articles/8-1961/v1/pdf?article_uuid=f40c1a70-3292-4db5-9d4a-8543dc0a57d2" title="Download PDF" class="button-link download pdf-download-helper" target=_blank>Get PDF</a> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-103_download_xml"></span> <a id=download-xml href="#" class="button-link download" title="Download XML">Get XML</a> </div> </div> <div class="article-interaction-info article-page"> <div class="cite-article-popup-wrapper article-page-interaction-box"> <div class="article-interaction-button cite-article-button" title="Cite this article" data-windowref=cite-article-popup-19463-1> <span class="f1r-icon icon-82_quote"></span> <a href="#" class="button-link cite-article-popup-link" title="Cite Article">Cite</a> </div> <div id=cite-article-popup-19463-1 class="popup-window-wrapper is-hidden"> <div class=cite-popup-background></div> <div class="popup-window top-popup cite-this-article-box research-layout"> <div class="popup-window-title small cite-title">How to cite this article</div> <span id=cite-article-text-19463-1 data-test-id=copy-citation_text> <span class="article-title-and-info in-popup">Rossignol J, Polivka L, Maouche-Chrétien L <em>et al.</em> Recent advances in the understanding and therapeutic management of mastocytosis [version 1; peer review: 4 approved]</span>. <i>F1000Research</i> 2019, <b>8</b>(F1000 Faculty Rev):1961 (<a class=new-orange href="https://doi.org/10.12688/f1000research.19463.1" target=_blank>https://doi.org/10.12688/f1000research.19463.1</a>) </span> <div class="popup-window-title small margin-top-20 margin-bottom-20 note"> <strong>NOTE:</strong> it is important to ensure the information in square brackets after the title is included in all citations of this article. </div> <div class=float-right> <button class="secondary no-fill orange-text-and-border margin-right-20 close-cite-popup uppercase">Close</button> <button id=copy-citation-details class="secondary orange copy-cite-article-version uppercase js-clipboard" title="Copy the current citation details to the clipboard." data-clipboard-target="#cite-article-text-19463-1" data-test-id=copy-citation_button>Copy Citation Details</button> </div> </div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-76_download_file"></span> <a id=export-citation href="#" class="button-link download" title="Export Citation">Export</a> </div> <div class="modal-window-wrapper is-hidden"> <div id=export-citation-popup class="modal-window padding-20"> <div class=modal-window-close-button></div> <div class=modal-window-title>Export Citation</div> <div class=modal-window-row> <div> <input type=radio name=export-citation-option value=WORKSPACE /> <span class=radio-label>Sciwheel</span> </div> <div> <input type=radio name=export-citation-option value=ENDNOTE /> <span class=radio-label>EndNote</span> </div> <div> <input type=radio name=export-citation-option value=REF_MANAGER /> <span class=radio-label>Ref. Manager</span> </div> <div> <input type=radio name=export-citation-option value=BIBTEX /> <span class=radio-label>Bibtex</span> </div> <div> <input type=radio name=export-citation-option value=PROCITE /> <span class=radio-label>ProCite</span> </div> <div> <input type=radio name=export-citation-option value=SENTE /> <span class=radio-label>Sente</span> </div> </div> <div class=modal-window-footer> <button class=general-white-orange-button id=export-citation-submit>EXPORT</button> </div> <div class=default-error style="display: none;">Select a format first</div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-90_track"></span> <a class="button-link track-article" data-article-id=19463 id=track-article-signin-19463 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/19463?target=/articles/8-1961/v1">Track</a> </div> </div> <div class="article-interaction-info article-page"> <div class="article-interaction-button email-article"> <span class="f1r-icon icon-6_email"></span> <a href="#" class=button-link title="Email this article">Email</a> </div> <div class="email-article-version-container small-tooltip _chrome-fix"> <div class=close-icon><span class="f1r-icon icon-3_close_big"></span></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=21341 /> <input name=articleId type=hidden value=19463 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-34_share"></span> <a href="#" class="button-link last addthis_button share-article" title="Share this article">Share</a> </div> </div> </div> <div id=article-interaction-control-tab class=article-interaction-control-tab> <div id=hide-article-interaction class=article-interaction-control title="Hide Toolbox">&#9644;</div> <div id=show-article-interaction class="article-interaction-control open" title="Show Toolbox">&#10010;</div> </div> </div> <div class="article-header-information article-page"> <div class="f1r-article-mobile article-heading-bar"></div> <div class="article-type article-display">Review </div> <div class="article-title-and-info article-view highlighted-article" id=anchor-title> <h1>Recent advances in the understanding and therapeutic management of mastocytosis</h1><span class=other-info> [version 1; peer review: 4 approved]</span> </div> <div class=article-subtitle></div> <div class=f1r-article-desk> <div class="authors _mdl-layout"><span class="">Julien Rossignol<sup>1-3</sup><sup>*</sup>,&nbsp;</span><span class="">Laura Polivka<sup>1,3,4</sup><sup>*</sup>,&nbsp;</span><span class="">Leila Maouche-Chr&eacute;tien<sup>1,3</sup>,&nbsp;</span><span class="">Laurent Frenzel<sup>1,3,5</sup>,&nbsp;</span><span class="">Patrice Dubreuil<sup>1,6</sup>,&nbsp;</span><span class=""><a href="mailto:ohermine@gmail.com" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Olivier Hermine</span></a><a href="https://orcid.org/0000-0003-2574-3874" target=_blank id=author-orcid-5><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=author-orcid-5><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0003-2574-3874</div><sup>1,3,5</sup></span></div> </div> <div class=f1r-article-mobile> <div class="authors _mdl-layout"><span class="">Julien Rossignol<sup>1-3</sup><sup>*</sup>,&nbsp;</span><span class="">Laura Polivka<sup>1,3,4</sup><sup>*</sup>,&nbsp;</span><a href="#" class=article-page-expand-authors>[...]&nbsp;</a><span class=article-page-hidden-authors>Leila Maouche-Chr&eacute;tien<sup>1,3</sup>,&nbsp;</span><span class=article-page-hidden-authors>Laurent Frenzel<sup>1,3,5</sup>,&nbsp;</span><span class="">Patrice Dubreuil<sup>1,6</sup>,&nbsp;</span><span class=""><a href="mailto:ohermine@gmail.com" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Olivier Hermine</span></a><a href="http://orcid.org/0000-0003-2574-3874" target=_blank id=mauthor-orcid-5><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=mauthor-orcid-5><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0003-2574-3874</div><sup>1,3,5</sup></span><span class="author-display-control article-page-expand-authors f1r-icon icon-20_plus_big"></span><span class="author-display-control article-page-hidden-authors f1r-icon icon-12_minus_big"></span></div> </div> <div class="authors extra-info"> <sup>*</sup> Equal contributors </div> <div class=f1r-article-mobile> <div class=article-pubinfo-mobile> PUBLISHED 22 Nov 2019 </div> </div> <span class=Z3988 title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft_id=info:doi/10.12688%2Ff1000research.19463.1"></span> <div class=f1r-article-desk> <div class="contracted-details first"> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> <sup>1</sup> French Reference Center for Mastocytosis (CEREMAST), Necker Children's Hospital, APHP, Paris, France<br/> <sup>2</sup> Department of Hematology, Gustave Roussy Institute, Paris-Saclay University, Villejuif, France<br/> <sup>3</sup> Imagine Institute, Paris University, INSERM U 1183, Paris, France<br/> <sup>4</sup> Centre de Recherche en Canc&eacute;rologie de Marseille, Inserm U1068, Marseille, France<br/> <sup>5</sup> Department of Hematology, Necker Children's Hospital, APHP, Paris, France<br/> <sup>6</sup> Department of Dermatology, Necker Children's Hospital, APHP, Paris, France<br/> <p> <div class=margin-bottom> Julien Rossignol <br/> <span>Roles: </span> Conceptualization, Writing – Original Draft Preparation </div> <div class=margin-bottom> Laura Polivka <br/> <span>Roles: </span> Conceptualization, Writing – Original Draft Preparation </div> <div class=margin-bottom> Leila Maouche-Chr&eacute;tien <br/> <span>Roles: </span> Writing – Review & Editing </div> <div class=margin-bottom> Laurent Frenzel <br/> <span>Roles: </span> Writing – Review & Editing </div> <div class=margin-bottom> Patrice Dubreuil <br/> <span>Roles: </span> Writing – Review & Editing </div> <div class=margin-bottom> Olivier Hermine <br/> <span>Roles: </span> Conceptualization, Writing – Original Draft Preparation, Writing – Review & Editing </div> </p> </div> </div> </div> <div class=f1r-article-mobile> <div class="article-page-section-box margin-bottom-40 research-layout"> <span class=box-title> <span class="f1r-icon icon-85_peer_review"></span> OPEN PEER REVIEW </span> <button class="tertiary grey float-right" data-scrollto=article-reports>DETAILS</button> <div class="status-row referee-reports-container"> REVIEWER STATUS <span class=status-icons> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=60136-56547></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=60138-56549></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=60137-56550></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=60132-56548></span> </span> </div> </div> </div> </div> <h2 class="article-headings article-page-abstract" id=anchor-abstract> <span class="f1r-article-mobile-inline abstract-heading-border"></span> Abstract </h2> <div class="article-abstract article-page-general-text-mobile research-layout"> <div class="abstract-text is-expanded"> Mastocytosis is a rare disease due to the abnormal accumulation of mast cells in various tissues. Its clinical presentation is heterogeneous depending on mast cell infiltration and mediators release. In some cases, it is associated with hematological malignancies. Prognosis varies from very good with a life expectancy similar to the general population in indolent forms of the disease to a survival time of just a few months in mast cell leukemia. Although in most cases a somatic <i>KIT </i>D816V mutation is found in tumor mast cells, the physiopathology of the disease is not yet fully understood. Additional germline and somatic mutations may explain this heterogeneity. Treatments aim at blocking effect of mast cell mediators, reducing mast cell activation and tumor burden. New drugs mainly directed against the tyrosine kinase activity of KIT have dramatically changed the quality of life and prognosis of mast cell diseases. Present and future therapeutic strategies are discussed in this review. </div> <div class=abstract-for-mobile> <div class="margin-top-30 padding-bottom-30 research-layout is-centered"> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border show" style="display: none;"> READ ALL <span class="f1r-icon icon-14_more_small orange vmiddle big"></span> </button> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border hide"> READ LESS <span class="f1r-icon icon-10_less_small orange vmiddle big"></span> </button> </div> </div> </div> <div class=clearfix></div> <div class="article-context no-divider"> <div class="article-abstract article-page-general-text-mobile research-layout generated-article-body"> <h2 class=main-title>Keywords</h2> <p class="u-mb--0 u-pb--2"> Mastocytosis, physiopathology, treatment, management, leukemia, mast cell </p> </div> </div> <div class=article-information> <span class="info-separation padding-bottom"> <div id=corresponding-author-icon class="email-icon float-left"> <span class="f1r-icon icon-6_email orange"></span> <div id=corresponding-author-window class="margin-top-20 popup-window-wrapper is-hidden"> <div class="popup-window corresponding-authors-popup"> <div class=corresponding-author-container> <div class="popup-window-title small">Corresponding Author(s)</div> <div class=authors> Olivier Hermine (<a href="mailto:ohermine@gmail.com">ohermine@gmail.com</a>) </div> </div> <div class="margin-top margin-bottom float-left"> <button id=close-popup-window class=general-white-orange-button>Close</button> </div> </div> </div> </div> <span class="icon-text float-left" data-test-id=box-corresponding-author> <b>Corresponding author:</b> Olivier Hermine </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom competing-interests-display"> <span class=competing-interests-title>Competing interests:</span> Julien Rossignol serves on an advisory board for Novartis, and Olivier Hermine and Patrice Dubreuil serve on an advisory board for AB science. All other authors declare that they have no competing interests. </span> <div class="info-separation padding-bottom grant-information-display"> <span class=grant-information-title>Grant information:</span> The author(s) declared that no grants were involved in supporting this work. </div> <span class="f1r-article-desk info-separation padding-bottom"> <span class="copywrite-icon float-left"> <span class="f1r-icon icon-100_open_access"></span> </span> <span class="icon-text float-left" data-test-id=box-copyright-text> <b>Copyright:</b>&nbsp; © 2019 Rossignol J <em>et al</em>. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom" data-test-id=box-how-to-cite> <b>How to cite:</b> <span class="article-title-and-info in-article-box"> Rossignol J, Polivka L, Maouche-Chrétien L <em>et al.</em> Recent advances in the understanding and therapeutic management of mastocytosis [version 1; peer review: 4 approved]</span>. <i>F1000Research</i> 2019, <b>8</b>(F1000 Faculty Rev):1961 (<a href="https://doi.org/10.12688/f1000research.19463.1" target=_blank>https://doi.org/10.12688/f1000research.19463.1</a>) </span> <span class=info-separation data-test-id=box-first-published><b>First published:</b> 22 Nov 2019, <b>8</b>(F1000 Faculty Rev):1961 (<a href="https://doi.org/10.12688/f1000research.19463.1" target=_blank>https://doi.org/10.12688/f1000research.19463.1</a>)</span> <span class=info-separation data-test-id=box-latest-published><b>Latest published:</b> 22 Nov 2019, <b>8</b>(F1000 Faculty Rev):1961 (<a href="https://doi.org/10.12688/f1000research.19463.1" target=_blank>https://doi.org/10.12688/f1000research.19463.1</a>)</span> </div> <div class=clearfix></div> <div id=article-context class=article-context> <div id=article1-body class=generated-article-body><h2 class=main-title id=d25892e271>Introduction</h2><p class="" id=d25892e274>Mastocytosis covers a spectrum of disease characterized by the clonal expansion and accumulation of mast cells (MCs) in the skin and in various internal organs, including the bone marrow (BM), spleen, lymph nodes, and gastrointestinal tract<sup><a href="#ref-1">1</a>,<a href="#ref-2">2</a></sup>. The disease presentation is heterogeneous and ranges from cutaneous mastocytosis (CM), which often resolves spontaneously in children, to acute MC leukemia (MCL), with a survival time of just a few months.</p><p class="" id=d25892e284>In 2016, the World Health Organization (WHO) classified types of mastocytosis into three main groups: CM, with involvement limited to the skin, systemic mastocytosis (SM), with the additional infiltration of tissues other than the skin, and MC sarcoma<sup><a href="#ref-3">3</a></sup>. SM is then subdivided into indolent SM (ISM) and, if organ infiltration leads to organ dysfunction, advanced SM (AdvSM). CM and ISM are by far the most frequent subtypes. Although patients with CM or ISM have a normal life expectancy, their quality of life may be impaired by symptoms related to MC activation<sup><a href="#ref-4">4</a></sup>. In contrast, AdvSM is associated with a decrease in life expectancy in the vast majority of patients; this is because of abnormal infiltration of MCs into various organs and thus impairment of the latter’s physiological functions (<a href="#T1">Table 1</a>).</p><a name=T1 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 1. The 2016 revision of the World Health Organization classification of mastocytosis<sup><a href="#ref-3">3</a></sup>.</h3></div><table xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d25892e313 class=n-a></a><tbody><a name=d25892e315 class=n-a></a><tr><a name=d25892e317 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d25892e319 class=n-a></a> <b>•&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cutaneous mastocytosis</b> <br class=br>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Urticaria pigmentosa, maculopapular cutaneous<br class=br>mastocytosis, diffuse cutaneous mastocytosis, mastocytoma<br class=br>of skin<br class=br>•&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>Systemic mastocytosis</b> <br class=br>a.&nbsp;&nbsp;&nbsp;&nbsp;Indolent systemic mastocytosis (ISM)<a href="#TFN">*</a><br class=br>b.&nbsp;&nbsp;&nbsp;&nbsp;Smoldering systemic mastocytosis (SSM)<a href="#TFN">*</a><br class=br>c.&nbsp;&nbsp;&nbsp;&nbsp;Systemic mastocytosis with an associated hematological<br class=br>neoplasm (SM-AHN)<a href="#TFN1">†</a><br class=br>d.&nbsp;&nbsp;&nbsp;&nbsp;Aggressive systemic mastocytosis (ASM)<a href="#TFN">*</a><br class=br>e.&nbsp;&nbsp;&nbsp;&nbsp;Mast cell leukemia (MCL)<br class=br>•&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<b>Mast cell sarcoma (MCS)</b> </td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=d25892e368 class=n-a></a><p id=TFN> *For a full diagnosis of these subtypes, information on B and C findings is required but may not be available at the time of the initial tissue diagnosis.</p><p id=TFN1>†This category is equivalent to the previously described “systemic mastocytosis with an associated clonal hematologic non-mast cell lineage disease”. AHNMD and AHN can be used synonymously.</p></div></div></div><p class="" id=d25892e379>Mastocytosis is strongly linked to somatic mutations in the <i>KIT</i> gene (and especially the <i>KIT</i> D816V mutation) coding for the tyrosine kinase receptor KIT, which lead to constitutive activation<sup><a href="#ref-5">5</a></sup>. However, it is now accepted that the <i>KIT</i> D816V mutation does not fully explain the spectrum of mastocytosis diseases. Recent studies of AdvSM have shown that other somatic genetic determinants (typically involving epigenetic regulators) can explain the disease’s heterogeneity. Most of these variants are associated with myeloid neoplasms and may worsen the prognosis<sup><a href="#ref-6">6</a>,<a href="#ref-7">7</a></sup>. In other cases in which <i>KIT</i> mutations are not found, the disease’s physiopathology has yet to be characterized.</p><p class="" id=d25892e407>The therapeutic management of mastocytosis is still a challenge for the physician<sup><a href="#ref-8">8</a></sup>. For patients with ISM, the treatment objective is to decrease the severity of MC activation and thus improve quality of life. Nevertheless, the treatment must be well tolerated and, if possible, devoid of short- and long-term side effects. In AdvSM, the main treatment goal is to prolong survival in patients with comorbidities and poor general status.</p><p class="" id=d25892e414>Here, we will review new insights into the diagnosis, pathogenesis, and therapeutic management of mastocytosis and cover perspectives for research into this complex disease.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d25892e420>Diagnosis</h2><p class="" id=d25892e423>Mastocytosis can potentially affect all of the organs and can cause a wide variety of clinical manifestations<sup><a href="#ref-1">1</a></sup>. The clinical signs are categorized into two types: those directly related to MC infiltration (skin, spleen, bone, etc.) and those related to MC activation.</p><p class="" id=d25892e430>Since skin involvement is easy to see, most cases of mastocytosis are revealed by the cutaneous manifestations like flushes, pruritus, and specific lesions. Alternatively, mastocytosis may be diagnosed after patients present with various non-specific symptoms that mimic conditions such as irritable/inflammatory bowel disease, chronic fatigue syndrome, fibromyalgia, and osteoarthritis. Constitutional symptoms (such as fatigue, pain, and neurologic and psychiatric symptoms) are also frequent but may not prompt a diagnosis of mastocytosis in the absence of skin involvement. Recurrent, severe, idiopathic anaphylaxis is more frequent in patients with mastocytosis and is especially associated with Hymenoptera stings, food allergy, exercise, and adverse drug reactions. The REMA score that includes gender, tryptase level, and clinical signs like syncope might be a useful decision-support tool, i.e. for deciding whether or not to perform the full diagnostic work-up for mastocytosis in patients with anaphylaxis, particularly in idiopathic cases or following Hymenoptera stings<sup><a href="#ref-9">9</a>,<a href="#ref-10">10</a></sup>. Recently, Carter <i>et al</i>. have reported the “NIH Idiopathic Clonal Anaphylaxis Score” using the aforementioned criteria with allele-specific quantitative PCR for the <i>KIT</i> D816V mutation. Interestingly, this score has better positive and negative predictive value than the REMA score<sup><a href="#ref-11">11</a></sup>.</p><p class="" id=d25892e450>Early onset osteoporosis is a classical manifestation of mastocytosis and typically involves trabecular bones. Less frequently, the disease is diagnosed during investigations of an associated hematologic neoplasm, such as a myeloproliferative disorder, myelodysplastic disease, or acute myeloid leukemia.</p><p class="" id=d25892e453>Lesions associated with MC infiltration are secondary to increased proliferation and survival of pathological MCs. On the other hand, the signs related to MC activation are secondary to the release of intracellular mediators after activation of the MC. Schematically, three phases succeed each other during this activation<sup><a href="#ref-12">12</a></sup>. First, MC degranulation of prestored mediators occurs a few seconds after triggering activation. These mediators include histamine, tryptase, proteoglycan, and cytokines. This first step is followed by the second phase characterized by the release of neo-synthesized mediators such as prostaglandin (PGD2), leukotrienes, and platelet-activating factor. Early mediators (histamine, PGD2, and leukotrienes) contribute to most of the signs of MC activation (pruritus, urticaria, flushing, hypotension, anaphylactic shock, edema, abdominal pain, and diarrhea). Finally, MCs secrete pro-inflammatory cytokines (TNFα, IL-1, and IL-6), pro-TH2 cytokines (IL-5 and IL-13), and other cytokines (TGFβ, VEGF, and FGF) that may participate in tissue lesions.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d25892e463>Classification</h2><p class="" id=d25892e466>Owing to the heterogeneity of the disease, and in order to better evaluate the prognosis and define treatment goals and endpoints, the WHO defined mastocytosis as a specific entity. Hence, because of its unique clinical and pathologic features, mastocytosis is no longer considered a subgroup of myeloproliferative neoplasms. Mastocytosis is classified into three main groups: CM (i.e. involving only the skin), SM (involving organs other than the skin), and MC sarcoma<sup><a href="#ref-3">3</a></sup>. Five major variants of SM have been defined: ISM, smoldering SM (SSM), SM with an associated hematologic neoplasm (SM-AHN), aggressive SM (ASM), and MCL (<a href="#T1">Table 1</a>).</p><p class="" id=d25892e476>CM requires a histologic confirmation of MC infiltration into the skin and the absence of any other organ involvement (and especially not the BM)<sup><a href="#ref-13">13</a></sup>. Cutaneous lesions are then divided into maculopapular CM (MPCM, also known as urticaria pigmentosa), diffuse CM, and localized mastocytoma of the skin. Telangiectasia macularis eruptiva perstans is a controversial clinical entity and was not recognized by the WHO. Although CM lesions are present in CM and SM at all ages, they are especially visible in all pediatric cases and less frequent in older adults. Therefore, CM is by far the most common form of mastocytosis in childhood, whereas AdvSM is extremely rare. However, the frequency of isolated CM is difficult to evaluate because BM aspirates and biopsies are rarely collected in children. Mastocytoma (a hemispheric, firm nodule) is the most common cutaneous manifestation of mastocytosis observed before the age of 3 months. Two distinct forms of MPCM have been recognized in children: a variant characterized by monomorphic, small lesions (formerly called urticaria pigmentosa) and one characterized by polymorphic (often large) lesions; these are now referred to as MPCM-small lesions and MPCM-large lesions, respectively<sup><a href="#ref-14">14</a></sup>. Diffuse CM is a rare variant that generally presents during the neonatal period. It is characterized by generalized erythema and is usually associated with pachydermia. In adult-onset mastocytosis, MPCM-small lesions are by far the most common cutaneous manifestations; other forms are very rare.</p><p class="" id=d25892e487>When the mastocytosis develops in adulthood, it is usually systemic. However, it is likely that some of these cases will be diagnosed as CM if high-sensitivity techniques are not used to detect systemic MC involvement. Nevertheless, in a trial of masitinib’s efficacy, the clinical response was better in cases with documented systemic involvement, suggesting that CM and SM are indeed distinct entities<sup><a href="#ref-15">15</a></sup>. A diagnosis of SM requires the documentation of mastocytosis away from the skin. The BM and the gastrointestinal tract are frequently involved, although MC infiltration can be found in other organ systems (bones, the liver, etc.).</p><p class="" id=d25892e494>To further characterize the disease, its severity must be characterized (<a href="#f1">Figure 1</a>)<sup><a href="#ref-3">3</a></sup>. The disease features are referred to as “B findings” if a high MC burden and an expansion of the neoplastic process into multiple hematopoietic lineages are present, with no obvious impairments in organ function, and “C findings” if the MC infiltration has produced organ dysfunction (<a href="#T2">Table 2</a>)<sup><a href="#ref-3">3</a>,<a href="#ref-16">16</a></sup>. Both ISM and ASM can be associated with a hematologic neoplasm (i.e. SM-AHN). Most hematologic malignancies associated with mastocytosis are of myeloid origin (myelodysplastic syndrome, acute myeloid leukemia, and myeloproliferative neoplasm). In order to define the best therapeutic strategy in cases of SM-AHN, it is essential to assess whether C findings are due to the SM or the AHN.</p><a name=f1 class=n-a></a><div class="fig panel clearfix"><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/21341/1e1057d9-4d41-44c2-9059-736d506ee195_figure1.gif"><img alt="1e1057d9-4d41-44c2-9059-736d506ee195_figure1.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/21341/1e1057d9-4d41-44c2-9059-736d506ee195_figure1.gif"></a><div class=caption><h3>Figure 1. Diagnostic flow chart for mastocytosis.</h3><p id=d25892e525>AHN, associated hematologic neoplasm; ASM-AHN, aggressive systemic mastocytosis with an associated hematologic neoplasm; BM, bone marrow; ISM, indolent systemic mastocytosis; MCL, mast cell leukemia; SM-AHN, systemic mastocytosis with an associated hematologic neoplasm; SSM, smoldering systemic mastocytosis; SSM-AHN, smoldering systemic mastocytosis with an associated hematologic neoplasm.</p></div></div><a name=T2 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 2. B and C findings for the diagnosis of systemic mastocytosis.</h3></div><table xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d25892e543 class=n-a></a><thead><a name=d25892e545 class=n-a></a><tr><a name=d25892e547 class=n-a></a><th align=center colspan=1 rowspan=1 valign=top><a name=d25892e549 class=n-a></a>B-findings</th><th align=center colspan=1 rowspan=1 valign=top><a name=d25892e552 class=n-a></a>C-findings</th></tr></thead><tbody><a name=d25892e557 class=n-a></a><tr><a name=d25892e559 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d25892e561 class=n-a></a>(1) High MC burden :<br class=br>Infiltration grade (MC) in BM &gt; 30% in<br class=br>histology and serum tryptase 200 ng/ml<br class=br> <br class=br>(2) Dysmyelopoiesis with normal blood<br class=br>counts or slight persisting deviation without<br class=br>progression<br class=br> <br class=br>(3) Organomegaly (<b>without impaired</b><br class=br><b>organ function</b>) :<br class=br>Palpaple hepatomegaly or/and<br class=br>lymphadenopathy palpable or visceral<br class=br>lymph node-enlargement found in US or CT<br class=br>(&gt;2cm) or/and palpable splenomegaly.</td><td colspan=1 rowspan=1 valign=top><a name=d25892e596 class=n-a></a>Organopathy (<b>with impaired organ function</b>) <b>:</b> <br class=br>(1) Bone marrow: cytopenia(s)<br class=br>ANC &lt; 1000/µl<br class=br>Hemoglobin &lt; 10g/dl<br class=br>Platelet &lt; 100 000/µl<br class=br> <br class=br>(2) Liver: palpable hepatomegaly with ascites,<br class=br>abnormal liver function tests and/or portal<br class=br>hypertension<br class=br> <br class=br>(3) Spleen: palpable splenomegaly with<br class=br>hypersplenism<br class=br> <br class=br>(4) GI tract: malabsorption with<br class=br>hypoalbuminemia and weight loss<br class=br> <br class=br>(5) Skeleton: bone lesions with large osteolyses<br class=br>or/and severe osteoporosis with pathologic<br class=br>fractures</td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=d25892e649 class=n-a></a><p id=d25892e651> ANC, absolute neutrophil count; BM, bone marrow; CT, computed tomography; GI, gastrointestinal; Hb, hemoglobin; LN, lymph node; MC, mast cell; Plt, platelet; US, ultrasound. Adapted from Valent <i>et al</i>.<sup><a href="#ref-16">16</a></sup></p></div></div></div><p class="" id=d25892e663>MCL is characterized by the presence of an abnormally high proportion of MCs (&gt;20%) on BM aspirate smears. Although MCL is very rare, cases can be subclassified as acute MCL with C findings. Some patients with MCL do not exhibit C findings and present a protracted course. Although not included in the WHO classification, we may describe these patients as having chronic MCL with no C findings. Expression of the cell proliferation marker KI67 may distinguish between these two entities (personal communications).</p><p class="" id=d25892e666>At the French Reference Center for Mastocytosis (CEREMAST, Paris, France), the work-up for suspected mastocytosis includes diagnostic tests for mastocytosis, screening for B and C findings and osteoporosis, and an extensive evaluation of the functional impairments associated with MC activation. We always perform a BM aspirate and biopsy and investigate exon 17 <i>KIT</i> mutations in BM cells and the atypical CD2 and CD25 expression on MCs. If AdvSM is suspected (i.e. with the presence of C findings), we perform next-generation sequencing on BM cells and screen for any additional mutations that are characteristic of myelodysplastic or myeloproliferative disorders and have prognostic and therapeutic value. In routine clinical practice, any further investigations (imaging or skin, intestinal tract, or liver biopsies, etc.) are usually prompted by abnormal clinical and laboratory features. In children, we perform only a BM aspirate and biopsy when AdvSM is suspected and the tryptase level is abnormally elevated (&gt;200 ng/ml). In view of the high frequency of mutations in <i>KIT</i> exons 8 to 13 and 17, this gene is always sequenced in suspected cases of childhood-onset mastocytosis.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d25892e678>Pathogenesis</h2><div class=section><a name=d25892e681 class=n-a></a><h3 class=section-title>New insights into mast cell ontogeny</h3><p class="" id=d25892e686>Recently, Gentek <i>et al</i>. reported that, like macrophages, MCs have two hematopoietic origins in the mouse<sup><a href="#ref-17">17</a></sup>. Unlike MCs in other organs, MCs in the embryonic skin are derived from the yolk sac. These MCs persist after birth before being gradually replaced by the definitive adult MCs. Yolk-sac-derived MCs differ phenotypically from their BM-derived counterparts and have a distinct gene expression pattern. These newly discovered differences might explain the complete, spontaneous remission observed in more than 70% of cases of childhood-onset mastocytosis.</p></div><div class=section><a name=d25892e697 class=n-a></a><h3 class=section-title>KIT mutations do not account for all mastocytosis phenotypes</h3><p class="" id=d25892e702>More than 85% of patients with adult-onset mastocytosis present a somatic gain-of-function mutation in the <i>KIT</i> gene coding for the KIT transmembrane tyrosine kinase receptor<sup><a href="#ref-18">18</a></sup>. The most frequently detected mutation leads to the substitution of an aspartic acid by a valine (D816V) in the second catalytic domain, resulting in constitutive kinase activity. In turn, this promotes MC activation, survival, and proliferation independently of KIT’s ligand (stem cell factor [SCF]). Under physiological conditions, SCF is critical for MC proliferation, differentiation, survival, and migration. Stimulation (by IgE or otherwise) enhances MC activation through the Ras-MAP kinase, SRC, STAT, and PI3K/AKT pathways. A somatic <i>KIT</i> mutation is present in around 80% of cases of childhood-onset mastocytosis. However, in contrast to adult cases, only 42% of the children present a mutation in codon 816 (exon 17); 44% of cases have a mutation outside exon 17 (mostly in the fifth Ig loop of the KIT extracellular domain, encoded by exons 8 and 9)<sup><a href="#ref-19">19</a></sup>. Although all of these <i>KIT</i> mutations cause the constitutive activation of kinase activity, they cannot fully explain the clonal expansion of MCs and the heterogeneous symptoms observed in different types of mastocytosis. Patients harboring the same mutation can present with very different clinical pictures. In childhood-onset mastocytosis, complete spontaneous remission is typically observed at puberty, despite the presence of <i>KIT</i>-activating mutations, including the D816V mutation. Transgenic mice overexpressing <i>KIT</i> D816V exhibit slow expansion and indolent accumulation of MCs in the tissues, with incomplete penetrance, and they rarely develop aggressive mastocytosis<sup><a href="#ref-20">20</a></sup>. Although most patients with mastocytosis did not have a family history of MC disease, around 100 familial cases worldwide have been reported in the literature. However, only 13 of these presented with germline KIT mutations (A533D, M541L, Del419D, S451C, K509I, V559A, R634W, or N822I)<sup><a href="#ref-21">21</a>–<a href="#ref-31">31</a></sup>. In the mastocytosis cohort at the CEREMAST, familial forms appear to be more prevalent than in the literature. Indeed, about 7% of our patients have a first- or second-degree relative with mastocytosis. The majority of these relatives do not have a mutation in the <i>KIT</i> gene (unpublished data). Thus, <i>KIT</i> mutations do not account for all familial forms of the disease. Lastly, BaF3 cells overexpressing <i>KIT</i> D816V do not display a transformed phenotype and are even driven towards maturation by the mutation<sup><a href="#ref-32">32</a></sup>.</p><p class="" id=d25892e754>Taken as a whole, these observations strongly suggest the additional involvement of one or more germline or somatic mutations or polymorphisms in genes other than KIT; these would act synergistically with <i>KIT</i> mutations in the development of mastocytosis.</p></div><div class=section><a name=d25892e761 class=n-a></a><h3 class=section-title>Associated somatic mutations</h3><p class="" id=d25892e766>Somatic mutations in other genes (notably epigenetic regulator genes, such as <i>SRSF2, ASXL1, RUNX1</i>, and <i>TET2</i>) have been described in ASM and are often found in patients with a myeloid neoplasm. These mutations account for, at least to some extent, the different clinical entities in mastocytosis.</p><p class="" id=d25892e775>Several studies have investigated the prognostic impact of these additional mutations. Most of the mutations have been found in patients with AdvSM, and the presence and number of <i>SRSF2, ASXL1</i>, and <i>RUNX1</i> (S/A/R) mutations are associated with a poor prognosis, even in patients treated with midostaurin (<a href="#f2">Figure 2</a>)<sup><a href="#ref-33">33</a>–<a href="#ref-35">35</a></sup>. <i>In vitro</i> studies suggest that these mutations act in synergy with abnormal KIT signal transduction to induce MC survival and proliferation. However, the underlying molecular mechanisms have yet to be characterized.</p><a name=f2 class=n-a></a><div class="fig panel clearfix"><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/21341/1e1057d9-4d41-44c2-9059-736d506ee195_figure2.gif"><img alt="1e1057d9-4d41-44c2-9059-736d506ee195_figure2.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/21341/1e1057d9-4d41-44c2-9059-736d506ee195_figure2.gif"></a><div class=caption><h3>Figure 2. Advanced systemic mastocytosis: clonal architecture and prognosis.</h3><p id=d25892e807> <b>A</b>. A representation of the clonal architecture of the hematopoietic compartment in advanced mastocytosis. The associated mutations occur before the <i>KIT</i> mutation. <b>B</b>. An early D816V <i>KIT</i> mutation inside the hematopoietic progenitor compartment and the presence of <i>SRSF2</i>, <i>ASXL1</i>, <i>RUNX1</i> (S/A/R) mutations are associated with a poor outcome. A, <i>ASXL1</i> mutation; R, <i>RUNX1</i> mutation; S, <i>SRSF2</i> mutation.</p></div></div><p class="" id=d25892e845>Two studies have investigated the clonal architecture in SM-AHN. First, Schwaab and colleagues reported a correlation among the <i>KIT</i> allele burden, the number of colony-forming unit granulocytes monocytes (CFU-GM) bearing the D816V <i>KIT</i> mutation, and the severity of mastocytosis. This finding strongly suggests that an early D816V <i>KIT</i> mutation inside the hematopoietic progenitor compartment is associated with a poor outcome (<a href="#f2">Figure 2</a>)<sup><a href="#ref-6">6</a></sup>. The second study of mutations in both AHN and mastocytosis showed that the D816V <i>KIT</i> mutation could be found in CD15<sup>+</sup> circulating cells and that MCs carried associated mutations. The results of a colony forming unit assay suggested that the associated mutations arise before the <i>KIT</i> mutation during hematopoiesis<sup><a href="#ref-33">33</a></sup>.</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d25892e882>Prognosis</h2><p class="" id=d25892e885>The prognosis for CM and ISM is excellent, as reported by Lim <i>et al</i>. in 2009<sup><a href="#ref-36">36</a></sup>. Indeed, patients with ISM in the USA have much the same life expectancy as the general population. However, the prognosis is poor for AdvSM, especially in elderly patients: median OS was 41 months for ASM, 24 months for SM-AHN, and 2 months for MCL in the aforementioned study reported by Lim <i>et al</i>.</p><p class="" id=d25892e898>Along with age, several prognostic factors have been reported. Splenomegaly and elevated alkaline phosphatase are predictive of a poor prognosis in both AdvSM and ISM. In AdvSM, the presence of one or more S/A/R mutations has a negative impact on the outcome.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d25892e905>Treatment</h2><p class="" id=d25892e908>Several new treatments have improved the prognosis and quality of life for patients with mastocytosis. The therapeutic objective depends on the type of mastocytosis, the prognosis, the patient’s age, and the presence or absence of an associated hematologic neoplasm.</p><div class=section><a name=d25892e911 class=n-a></a><h3 class=section-title>Cutaneous and indolent systemic mastocytosis: the main treatment objective is to decrease handicap and improve quality of life (<a href="#T3">Table 3</a> and <a href="#f3">Figure 3</a>)</h3><p class="" id=d25892e922>Patients with an indolent form of mastocytosis (like CM and ISM) can present two types of clinical symptoms: those related to MC activation syndrome (MCAS) and those related to MC infiltration (particularly skin infiltration). The treatment choice is therefore based on the signs that cause the most severe disability (<a href="#f3">Figure 3</a> and <a href="#f4">Figure 4</a>).</p><a name=T3 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 3. Completed clinical trials and large retrospective studies of indolent systemic mastocytosis or smoldering systemic mastocytosis.</h3></div><table xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d25892e942 class=n-a></a><thead><a name=d25892e944 class=n-a></a><tr><a name=d25892e946 class=n-a></a><th align=center colspan=1 rowspan=1><a name=d25892e948 class=n-a></a>Author (Journal)</th><th align=center colspan=1 rowspan=1><a name=d25892e951 class=n-a></a>Treatment</th><th align=center colspan=1 rowspan=1><a name=d25892e954 class=n-a></a>Patients</th><th align=center colspan=1 rowspan=1><a name=d25892e957 class=n-a></a>Type of study</th><th align=center colspan=1 rowspan=1><a name=d25892e960 class=n-a></a>ORR (%)</th><th align=center colspan=1 rowspan=1><a name=d25892e964 class=n-a></a>Follow up</th></tr></thead><tbody><a name=d25892e969 class=n-a></a><tr><a name=d25892e971 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d25892e973 class=n-a></a>Barete (Blood)<sup><a href="#ref-40">40</a></sup> </td><td align=center colspan=1 rowspan=1 valign=top><a name=d25892e980 class=n-a></a>Cladribine</td><td align=center colspan=1 rowspan=1 valign=top><a name=d25892e983 class=n-a></a>36</td><td align=center colspan=1 rowspan=1 valign=top><a name=d25892e986 class=n-a></a>Retrospective</td><td align=center colspan=1 rowspan=1 valign=top><a name=d25892e989 class=n-a></a>ORR: 92 %</td><td align=center colspan=1 rowspan=1 valign=top><a name=d25892e993 class=n-a></a>Duration of response: 44.5 months</td></tr><tr><a name=d25892e997 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d25892e999 class=n-a></a>Lim (Am. J.<br class=br>Hematol.)<sup><a href="#ref-41">41</a></sup> </td><td align=center colspan=1 rowspan=1 valign=top><a name=d25892e1008 class=n-a></a>Interferon</td><td align=center colspan=1 rowspan=1 valign=top><a name=d25892e1011 class=n-a></a>11</td><td align=center colspan=1 rowspan=1 valign=top><a name=d25892e1014 class=n-a></a>Retrospective</td><td align=center colspan=1 rowspan=1 valign=top><a name=d25892e1017 class=n-a></a>ORR: 60%</td><td align=center colspan=1 rowspan=1 valign=top><a name=d25892e1021 class=n-a></a>Duration of response: 12 months (with<br class=br>AdvSM)</td></tr><tr><a name=d25892e1027 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d25892e1029 class=n-a></a>Broesby-Olsen<br class=br>(Allergy)<sup><a href="#ref-42">42</a></sup> </td><td align=center colspan=1 rowspan=1 valign=top><a name=d25892e1038 class=n-a></a>Omalizumab</td><td align=center colspan=1 rowspan=1 valign=top><a name=d25892e1041 class=n-a></a>13</td><td align=center colspan=1 rowspan=1 valign=top><a name=d25892e1044 class=n-a></a>Retrospective</td><td align=center colspan=1 rowspan=1 valign=top><a name=d25892e1047 class=n-a></a>ORR: 78.6 %</td><td align=center colspan=1 rowspan=1 valign=top><a name=d25892e1051 class=n-a></a>Duration of treatment: 21 months</td></tr><tr><a name=d25892e1055 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d25892e1057 class=n-a></a>Lemal (JACI<br class=br>practice)<sup><a href="#ref-43">43</a></sup> </td><td align=center colspan=1 rowspan=1 valign=top><a name=d25892e1066 class=n-a></a>Omalizumab</td><td align=center colspan=1 rowspan=1 valign=top><a name=d25892e1069 class=n-a></a>56</td><td align=center colspan=1 rowspan=1 valign=top><a name=d25892e1072 class=n-a></a>Retrospective</td><td align=center colspan=1 rowspan=1 valign=top><a name=d25892e1075 class=n-a></a>ORR: 76.8%</td><td align=center colspan=1 rowspan=1 valign=top><a name=d25892e1079 class=n-a></a>Response at least &gt; 3 months (76.7%)</td></tr><tr><a name=d25892e1083 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d25892e1085 class=n-a></a>Vega-Ruiz (Leukemia<br class=br>Research)<sup><a href="#ref-44">44</a></sup> </td><td align=center colspan=1 rowspan=1 valign=top><a name=d25892e1094 class=n-a></a>Imatinib</td><td align=center colspan=1 rowspan=1 valign=top><a name=d25892e1097 class=n-a></a>11</td><td align=center colspan=1 rowspan=1 valign=top><a name=d25892e1100 class=n-a></a>Phase II</td><td align=center colspan=1 rowspan=1 valign=top><a name=d25892e1103 class=n-a></a>ORR: 55%</td><td align=center colspan=1 rowspan=1 valign=top><a name=d25892e1107 class=n-a></a>Duration of improvement lasted between 9<br class=br>and 36 months</td></tr><tr><a name=d25892e1114 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d25892e1116 class=n-a></a>Verstovsek<br class=br>(Clin Cancer Res)<sup><a href="#ref-45">45</a></sup> </td><td align=center colspan=1 rowspan=1 valign=top><a name=d25892e1125 class=n-a></a>Dasatinib</td><td align=center colspan=1 rowspan=1 valign=top><a name=d25892e1128 class=n-a></a>18</td><td align=center colspan=1 rowspan=1 valign=top><a name=d25892e1131 class=n-a></a>Phase II</td><td align=center colspan=1 rowspan=1 valign=top><a name=d25892e1134 class=n-a></a>ORR: 33%</td><td align=center colspan=1 rowspan=1 valign=top><a name=d25892e1138 class=n-a></a>Duration of symptomatic responses<br class=br>ranged from 3 to 18+ months</td></tr><tr><a name=d25892e1144 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d25892e1146 class=n-a></a>Lortholary (Lancet)<sup><a href="#ref-15">15</a></sup></td><td align=center colspan=1 rowspan=1 valign=top><a name=d25892e1152 class=n-a></a>Masitinib</td><td align=center colspan=1 rowspan=1 valign=top><a name=d25892e1155 class=n-a></a>masitinib<br class=br>n=71<br class=br>placebo<br class=br>n=64</td><td align=center colspan=1 rowspan=1 valign=top><a name=d25892e1164 class=n-a></a>Phase III</td><td align=center colspan=1 rowspan=1 valign=top><a name=d25892e1167 class=n-a></a>Cumulative response<br class=br>(≥75% symptom<br class=br>improvement)<br class=br>Masitinib: 18·7%<br class=br>Placebo: 7.4%</td><td align=center colspan=1 rowspan=1 valign=top><a name=d25892e1179 class=n-a></a>Duration of treatment: 18·9 months</td></tr><tr><a name=d25892e1183 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d25892e1185 class=n-a></a>Moraly (unpublished<br class=br>data, submitted for<br class=br>publication)</td><td align=center colspan=1 rowspan=1 valign=top><a name=d25892e1192 class=n-a></a>Rapamycine</td><td align=center colspan=1 rowspan=1 valign=top><a name=d25892e1195 class=n-a></a>11</td><td align=center colspan=1 rowspan=1 valign=top><a name=d25892e1198 class=n-a></a>Retrospective</td><td align=center colspan=1 rowspan=1 valign=top><a name=d25892e1201 class=n-a></a>ORR: 70%</td><td align=center colspan=1 rowspan=1 valign=top><a name=d25892e1205 class=n-a></a>Duration of treatment: 10.8 months</td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=d25892e1213 class=n-a></a><p id=d25892e1215> AdvSM, advanced systemic mastocytosis; ORR, overall response rate.</p></div></div></div><a name=f3 class=n-a></a><div class="fig panel clearfix"><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/21341/1e1057d9-4d41-44c2-9059-736d506ee195_figure3.gif"><img alt="1e1057d9-4d41-44c2-9059-736d506ee195_figure3.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/21341/1e1057d9-4d41-44c2-9059-736d506ee195_figure3.gif"></a><div class=caption><h3>Figure 3. Treatment flow chart for indolent and smoldering systemic mastocytosis.</h3><p id=d25892e1231>2CDA, cladribine; DXA, dual-energy X-ray absorptiometry; IFN, interferon; ISM, indolent systemic mastocytosis; SSM, smoldering mastocytosis; TKI, tyrosine kinase inhibitor.</p></div></div><a name=f4 class=n-a></a><div class="fig panel clearfix"><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/21341/1e1057d9-4d41-44c2-9059-736d506ee195_figure4.gif"><img alt="1e1057d9-4d41-44c2-9059-736d506ee195_figure4.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/21341/1e1057d9-4d41-44c2-9059-736d506ee195_figure4.gif"></a><div class=caption><h3>Figure 4. Treatment flow chart for advanced systemic mastocytosis.</h3><p id=d25892e1248>ASCT, allogeneic stem cell transplantation; AdvSM, advanced systemic mastocytosis; AHN, associated hematologic neoplasm; ASM, aggressive systemic mastocytosis; BM, bone marrow; ISM, indolent systemic mastocytosis; MCL, mast cell leukemia; SM-AHN, systemic mastocytosis with an associated hematologic neoplasm; SSM, smoldering systemic mastocytosis.</p></div></div><p class="" id=d25892e1256>The treatment of signs of MC activation is initially based on antihistamines (anti-H1 and anti-H2), leukotriene receptor inhibitors, and cromolyn. Although aspirin and NSAIDs may induce allergic and/or anaphylactic reactions, there is no absolute contra-indication to these drugs and they may even improve some symptoms like pains and flushing. For children with isolated mastocytoma and severe symptoms, the treatment of choice is topical corticosteroids with occlusive dressings. If this fails, excision <i>in toto</i> can be considered. Ultraviolet A (either alone or combined with oral psoralen) can be used in adolescents and adults to treat skin manifestations (especially pruritus) that are resistant to standard medications. It is essential to eliminate triggering factors (e.g. foods, medications, or environmental factors such as Hymenoptera stings) by testing for IgE-mediated allergy. These measures must be accompanied by patient education on epinephrine self-administration (especially in patients with a history of anaphylactic reactions)<sup><a href="#ref-8">8</a></sup>. Honeybee- and wasp-allergic patients with a history of severe reactions must be submitted to allergen-specific immunotherapy<sup><a href="#ref-37">37</a></sup>. Patients must be warned of the risk associated with anesthesia; for example, the French Society of Anesthesia &amp; Intensive Care Medicine has published specific guidelines on this topic. Most patients are improved by these initial therapeutic measures<sup><a href="#ref-38">38</a></sup>.</p><p class="" id=d25892e1274>In our experience, we prescribe anti-H1 medications almost systematically for MCAS, especially for pruritus, urticaria, flushing, recurrent hypotension/anaphylaxis, or neuropsychic manifestations. We use anti-H2 medication and cromolyn with or without a proton pump inhibitor for gastrointestinal symptoms. Leukotriene antagonists seem particularly effective for flushing and pollakiuria. We are currently testing the effect of NMDA receptor inhibitors (such as ketamine) in patients (about 20%) with fentanyl-refractory chronic pain<sup><a href="#ref-39">39</a></sup>. Our preliminary results suggest that these treatments can be efficient. Lastly, as there is no prospective study published so far on the role of bone-forming therapies for mastocytosis-associated osteoporosis, we are investigating the efficacy of denosumab in a phase III study (NCT03401060). In addition to signs of MC activation, patients may experience disability due to the psychological and social impact of the skin involvement in MPCM. It is difficult to accurately assess the disability related to acute and chronic symptoms. Several consultations are necessary to confirm the patient's willingness to accept the potential risks associated with certain treatments, particularly for esthetic reasons, because the treatment of cutaneous lesions requires the use of cytoreductive drugs.</p><p class="" id=d25892e1281>At present, there are no guidelines on MC activation that is refractory to antihistamine medications or on when cytoreductive drugs should be used. With the exception of masitinib, prospective clinical trials have not been performed. Hence, treatment choice is based solely on the specialist center’s own experience (<a href="#T3">Table 3</a>)<sup><a href="#ref-15">15</a>,<a href="#ref-40">40</a>–<a href="#ref-45">45</a></sup>.</p><p class="" id=d25892e1297> <b> <i>Tyrosine kinase inhibitors.</i> </b> Given the involvement of constitutive KIT tyrosine kinase activity in the pathophysiology of mastocytosis, several drugs used to block both BCR-ABL and KIT in cases of chronic myeloid leukemia have also been evaluated in SM.</p><p class="" id=d25892e1306>The results of several prospective studies of first-generation (imatinib) and second-generation (dasatinib and nilotinib) inhibitors have been disappointing, with low response rates<sup><a href="#ref-44">44</a>,<a href="#ref-45">45</a></sup>. On the molecular level, the presence of the D816V <i>KIT</i> mutation in the vast majority of cases of mastocytosis confers resistance to the above-mentioned inhibitors. We therefore reserve these treatments for the small proportion of patients who do not have a <i>KIT</i> exon 17 mutation; the results for MC activation and cutaneous involvement are encouraging.</p><p class="" id=d25892e1322>Masitinib was evaluated in the first phase III study of patients with CM or ISM and significant disability<sup><a href="#ref-15">15</a></sup>. Although masitinib lacks direct activity on the D816V <i>KIT</i> mutation, its action (particular on Lyn) appears to block MC degranulation <i>in vitro</i>. In Lortholary <i>et al</i>.’s study, masitinib had an acceptable safety profile and showed significant efficacy on symptoms; a reduction of more than 75% in symptoms was observed in 18.7% of the patients treated with the inhibitor and 7.4% of those treated with placebo (<i>P</i> = 0.0076). This drug is currently being evaluated in a confirmatory phase III trial.</p><p class="" id=d25892e1342> <b> <i>Cladribine.</i> </b> Cladribine has never been prospectively evaluated in SM, although long-term follow-up data from patients with SM have been reported retrospectively. This drug has a positive effect on both skin involvement and the symptoms of MC activation. Barete <i>et al</i>. studied cladribine treatment in 36 patients with ISM/SSM; the overall response rate was 92%, and the median response duration was 44.5 months<sup><a href="#ref-40">40</a></sup>. Although the treatment induced significant neutropenia and prolonged CD4<sup>+</sup> T-cell lymphopenia, the toxicity was mild and acceptable for an indolent disease. However, given the risk of secondary cancer observed in other indications, it is recommended to exclude patients with a history of cancer and to limit the number of courses of cladribine (0.14 mg/kg/day, for 5 days) to 6. We are currently looking at whether lower-dose maintenance treatment with cladribine might be as efficacious.</p><p class="" id=d25892e1361> <b> <i>Omalizumab.</i> </b> Omalizumab is an anti-IgE monoclonal antibody indicated in the treatment of asthma and chronic urticaria. Given the drug’s mode of action and lack of cytoreductive activity, it has been suggested that omalizumab can decrease the signs of MC activation associated with mastocytosis<sup><a href="#ref-42">42</a></sup>. The initial results in a small cohort were encouraging. In an analysis of the CEREMAST database, we reported on the largest-yet cohort of omalizumab-treated patients (n = 56) with indolent, cutaneous forms and MCAS<sup><a href="#ref-43">43</a></sup>. The results were particularly encouraging, with an overall response rate of 76.8% and reductions in all symptoms assessed, even the difficult-to-treat neuropsychiatric symptoms. Omalizumab is therefore an option that we often consider in patients who are very disabled by their signs of MC activation. Further work is needed to define the population that will benefit most from omalizumab treatment. At present, the optimal dosing frequency (150 to 300 mg every week to every four weeks) remains to be determined. Furthermore, omalizumab may be of value for Hymenoptera venom desensitization in patients with mastocytosis.</p><p class="" id=d25892e1378> <b> <i>Other options.</i> </b> Pegylated interferon (pegIFN) has been used for decades in the treatment of mastocytosis. It effectively reduces both the signs of MC activation and the extent of cutaneous lesions<sup><a href="#ref-41">41</a></sup>. The main limitation relates to the associated neuropsychiatric side effects in a patient population that frequently suffers from psychiatric signs in general and major depressive episodes in particular. However, pegIFN remains a valuable option, especially when other treatments are contraindicated or for cladribine sparing. PegIFN can be used also to treat the myeloproliferative disorders associated with mastocytosis.</p><p class="" id=d25892e1391>Rapamycin may also be a relevant treatment option in relapsed or refractory patients carrying the D816V <i>KIT</i> mutation. We found that <i>in vitro</i>, D816V-mutated MC lines (but not wild-type MC lines) were specifically sensitive to rapamycin<sup><a href="#ref-46">46</a></sup>. Even though the first-in-human results did not show significant efficacy, our study of a series of 24 patients (including 12 with ISM) highlighted a response rate of 70% (especially for the signs of MC activation), as could be expected from the <i>in vitro</i> data (unpublished data, submitted for publication). Efficacy on MPCM was also observed.</p></div><div class=section><a name=d25892e1408 class=n-a></a><h3 class=section-title>Advanced mastocytosis: the main objective is to prolong overall survival (<a href="#T4">Table 4</a> and <a href="#f4">Figure 4</a>)</h3><p class="" id=d25892e1419>Advanced mastocytosis is a spectrum of hematological malignancies with a poor prognosis. In eligible and particularly poor prognosis patients, the aim of the treatment is to induce remission to perform an allogeneic stem cell transplantation (ASCT) that remains the only current treatment with the potential to cure. Until recently, no targeted therapies were available for this difficult-to-treat set of MC diseases (<a href="#T4">Table 4</a>)<sup><a href="#ref-40">40</a>,<a href="#ref-41">41</a>,<a href="#ref-44">44</a>,<a href="#ref-45">45</a>,<a href="#ref-47">47</a>–<a href="#ref-50">50</a></sup>. Lately, impressive efficacy of midostaurin has been reported in the first large-scale phase II study in advanced mastocytosis, and so it was approved by the FDA in 2017. We will discuss below the main cytoreductive therapies used at our reference center.</p><a name=T4 class=n-a></a><div class="table-wrap panel clearfix"><div class=caption><h3>Table 4. Completed clinical trials and large retrospective studies for advanced mastocytosis.</h3></div><table xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d25892e1455 class=n-a></a><thead><a name=d25892e1457 class=n-a></a><tr><a name=d25892e1459 class=n-a></a><th align=center colspan=1 rowspan=1 valign=top><a name=d25892e1461 class=n-a></a>Author<br class=br>(Journal)</th><th align=center colspan=1 rowspan=1 valign=top><a name=d25892e1466 class=n-a></a>Treatment</th><th align=center colspan=1 rowspan=1 valign=top><a name=d25892e1469 class=n-a></a>Patients</th><th align=center colspan=1 rowspan=1 valign=top><a name=d25892e1472 class=n-a></a>Type of study</th><th align=center colspan=1 rowspan=1 valign=top><a name=d25892e1475 class=n-a></a>Non hematological<br class=br>AE (grade III/IV)</th><th align=center colspan=1 rowspan=1 valign=top><a name=d25892e1481 class=n-a></a>Response</th><th align=center colspan=1 rowspan=1 valign=top><a name=d25892e1484 class=n-a></a>Mediane<br class=br>response<br class=br>duration</th><th align=center colspan=1 rowspan=1 valign=top><a name=d25892e1491 class=n-a></a>Overall<br class=br>survival</th></tr></thead><tbody><a name=d25892e1498 class=n-a></a><tr><a name=d25892e1500 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d25892e1502 class=n-a></a>Lim (<i>Am J</i><br class=br><i>Hematol</i>.)<sup><a href="#ref-41">41</a></sup> </td><td align=center colspan=1 rowspan=1><a name=d25892e1515 class=n-a></a>Interferon α</td><td align=center colspan=1 rowspan=1><a name=d25892e1518 class=n-a></a>30</td><td align=center colspan=1 rowspan=1><a name=d25892e1521 class=n-a></a>Retrospective</td><td align=center colspan=1 rowspan=1><a name=d25892e1524 class=n-a></a>Asthenia,<br class=br>depression</td><td align=center colspan=1 rowspan=1><a name=d25892e1530 class=n-a></a>ORR: 50%</td><td align=center colspan=1 rowspan=1><a name=d25892e1533 class=n-a></a>12 months<br class=br>(with ISM)</td><td align=center colspan=1 rowspan=1><a name=d25892e1538 class=n-a></a>NA</td></tr><tr><a name=d25892e1542 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d25892e1544 class=n-a></a>Kluin-Nelemens<br class=br>(<i>Blood</i>)<sup><a href="#ref-47">47</a></sup> </td><td align=center colspan=1 rowspan=1><a name=d25892e1556 class=n-a></a>Cladribine</td><td align=center colspan=1 rowspan=1><a name=d25892e1559 class=n-a></a>6</td><td align=center colspan=1 rowspan=1><a name=d25892e1562 class=n-a></a>Phase II</td><td align=center colspan=1 rowspan=1><a name=d25892e1565 class=n-a></a>Infection, toxidermia</td><td align=center colspan=1 rowspan=1><a name=d25892e1569 class=n-a></a>ORR: 100%<br class=br>CR: 0%</td><td align=center colspan=1 rowspan=1><a name=d25892e1574 class=n-a></a>NA</td><td align=center colspan=1 rowspan=1><a name=d25892e1577 class=n-a></a>NA</td></tr><tr><a name=d25892e1581 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d25892e1583 class=n-a></a>Barete (<i>Blood</i>)<sup><a href="#ref-40">40</a></sup> </td><td align=center colspan=1 rowspan=1><a name=d25892e1593 class=n-a></a>Cladribine</td><td align=center colspan=1 rowspan=1><a name=d25892e1596 class=n-a></a>32</td><td align=center colspan=1 rowspan=1><a name=d25892e1599 class=n-a></a>Retrospective</td><td align=center colspan=1 rowspan=1><a name=d25892e1602 class=n-a></a>Infection</td><td align=center colspan=1 rowspan=1><a name=d25892e1606 class=n-a></a>ORR: 50%<br class=br>CR: 0%</td><td align=center colspan=1 rowspan=1><a name=d25892e1611 class=n-a></a>ASM: 30<br class=br>months<br class=br>SM-AHN: 57<br class=br>months</td><td align=center colspan=1 rowspan=1><a name=d25892e1620 class=n-a></a>Median: ASM:<br class=br>2.4 years<br class=br>SM-AHN: 6.5<br class=br>years</td></tr><tr><a name=d25892e1630 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d25892e1632 class=n-a></a>Vega-Ruiz<br class=br>(<i>Leukemia</i><br class=br><i>Research</i>)<sup><a href="#ref-44">44</a></sup> </td><td align=center colspan=1 rowspan=1><a name=d25892e1647 class=n-a></a>Imatinib</td><td align=center colspan=1 rowspan=1><a name=d25892e1650 class=n-a></a>9</td><td align=center colspan=1 rowspan=1><a name=d25892e1653 class=n-a></a>Phase II</td><td align=center colspan=1 rowspan=1><a name=d25892e1656 class=n-a></a>Ascites, diarrhea,<br class=br>asthenia, pain, rash</td><td align=center colspan=1 rowspan=1><a name=d25892e1662 class=n-a></a>ORR: 11%<br class=br>CR: 11%</td><td align=center colspan=1 rowspan=1><a name=d25892e1667 class=n-a></a>NA</td><td align=center colspan=1 rowspan=1><a name=d25892e1670 class=n-a></a>NA</td></tr><tr><a name=d25892e1674 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d25892e1676 class=n-a></a>Lim (<i>Am J</i><br class=br><i>Hematol</i>.)<sup><a href="#ref-41">41</a></sup> </td><td align=center colspan=1 rowspan=1><a name=d25892e1689 class=n-a></a>Imatinib</td><td align=center colspan=1 rowspan=1><a name=d25892e1692 class=n-a></a>19</td><td align=center colspan=1 rowspan=1><a name=d25892e1695 class=n-a></a>Retrospective</td><td align=center colspan=1 rowspan=1><a name=d25892e1698 class=n-a></a>Diarrhea, edema</td><td align=center colspan=1 rowspan=1><a name=d25892e1702 class=n-a></a>ORR: 20%<br class=br>CR: 0%</td><td align=center colspan=1 rowspan=1><a name=d25892e1707 class=n-a></a>19 months<br class=br>(with ISM)</td><td align=center colspan=1 rowspan=1><a name=d25892e1712 class=n-a></a>NA</td></tr><tr><a name=d25892e1717 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d25892e1719 class=n-a></a>Pagano (<i>Int J</i><br class=br><i>Hematol.</i>)<sup><a href="#ref-48">48</a></sup> </td><td align=center colspan=1 rowspan=1><a name=d25892e1732 class=n-a></a>Imatinib</td><td align=center colspan=1 rowspan=1><a name=d25892e1735 class=n-a></a>17</td><td align=center colspan=1 rowspan=1><a name=d25892e1738 class=n-a></a>Retrospective</td><td align=center colspan=1 rowspan=1><a name=d25892e1741 class=n-a></a>NA</td><td align=center colspan=1 rowspan=1><a name=d25892e1745 class=n-a></a>ORR: 29%<br class=br>CR: 5%</td><td align=center colspan=1 rowspan=1><a name=d25892e1750 class=n-a></a>NA</td><td align=center colspan=1 rowspan=1><a name=d25892e1753 class=n-a></a>NA</td></tr><tr><a name=d25892e1757 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d25892e1759 class=n-a></a>Verstovsek (<i>Clin</i><br class=br><i>Cancer Res</i>)<sup><a href="#ref-45">45</a></sup> </td><td align=center colspan=1 rowspan=1><a name=d25892e1772 class=n-a></a>Dasatinib</td><td align=center colspan=1 rowspan=1><a name=d25892e1775 class=n-a></a>15</td><td align=center colspan=1 rowspan=1><a name=d25892e1778 class=n-a></a>Phase II</td><td align=center colspan=1 rowspan=1><a name=d25892e1781 class=n-a></a>Pleural effusion,<br class=br>pains, nausea,<br class=br>asthenia</td><td align=center colspan=1 rowspan=1><a name=d25892e1789 class=n-a></a>ORR: 13%<br class=br>CR: 13%</td><td align=center colspan=1 rowspan=1><a name=d25892e1794 class=n-a></a>12 months</td><td align=center colspan=1 rowspan=1><a name=d25892e1797 class=n-a></a>Median:<br class=br>13 months</td></tr><tr><a name=d25892e1803 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d25892e1805 class=n-a></a>Gotlib (<i>NEJM</i>)<sup><a href="#ref-49">49</a></sup> </td><td align=center colspan=1 rowspan=1><a name=d25892e1815 class=n-a></a>Midostaurin</td><td align=center colspan=1 rowspan=1><a name=d25892e1818 class=n-a></a>116</td><td align=center colspan=1 rowspan=1><a name=d25892e1821 class=n-a></a>Phase II</td><td align=center colspan=1 rowspan=1><a name=d25892e1824 class=n-a></a>Nausea, diarrhea,<br class=br>fatigue</td><td align=center colspan=1 rowspan=1><a name=d25892e1830 class=n-a></a>ORR: 60%<br class=br>CR: 0%</td><td align=center colspan=1 rowspan=1><a name=d25892e1835 class=n-a></a>24.1 months</td><td align=center colspan=1 rowspan=1><a name=d25892e1838 class=n-a></a>Median: 33.9<br class=br>months</td></tr><tr><a name=d25892e1844 class=n-a></a><td colspan=1 rowspan=1 valign=top><a name=d25892e1846 class=n-a></a>Ustun (<i>JCO</i>)<sup><a href="#ref-50">50</a></sup> </td><td align=center colspan=1 rowspan=1><a name=d25892e1856 class=n-a></a>ASCT: MAC: 63%<br class=br>Geno-identical:<br class=br>60%</td><td align=center colspan=1 rowspan=1><a name=d25892e1863 class=n-a></a>57</td><td align=center colspan=1 rowspan=1><a name=d25892e1866 class=n-a></a>Retrospective</td><td align=center colspan=1 rowspan=1><a name=d25892e1869 class=n-a></a>1 year NRM: 20%</td><td align=center colspan=1 rowspan=1><a name=d25892e1873 class=n-a></a>ORR: 70%<br class=br>CR: 28%</td><td align=center colspan=1 rowspan=1><a name=d25892e1878 class=n-a></a>20 months</td><td align=center colspan=1 rowspan=1><a name=d25892e1881 class=n-a></a>3 years overall<br class=br>survival: 57%</td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=d25892e1891 class=n-a></a><p id=d25892e1893> AdvSM, advanced systemic mastocytosis; AE, adverse events; ASCT, allogeneic stem cell transplantation; ASM, aggressive systemic mastocytosis; CR, complete response; ISM, indolent systemic mastocytosis; MAC, myeloablative conditioning; NA, not available; NRM, non-relapse mortality; ORR, overall response rate; SM-AHN, systemic mastocytosis with an associated hematologic neoplasm.</p></div></div></div><p class="" id=d25892e1899> <b> <i>Midostaurin.</i> </b> The broad-spectrum tyrosine kinase inhibitor midostaurin has activity against D816V <i>KIT</i> mutations. The results of the first large-scale clinical trial in patients with AdvSM (n = 116) were published in 2016<sup><a href="#ref-49">49</a></sup>. Overall, 60% of the patients treated with midostaurin exhibited a response. The safety profile was acceptable, and the most frequent adverse events affected the gastrointestinal tract (nausea and diarrhea). The median response duration was 24.1 months, and the median overall survival time was 33.9 months. Interestingly, the midostaurin response rates were similar in all of the subgroups of patients with ASM, including those with AHN. However, histologically complete responses were rarely observed, and treatment had to be maintained. In our opinion, midostaurin is currently the first-line treatment of choice for first-line AdvSM.</p><p class="" id=d25892e1915> <b> <i>Cladribine.</i> </b> Cladribine has been studied to some extent, but it is not considered as the standard of care<sup><a href="#ref-47">47</a></sup>. In the above-mentioned study by Barete <i>et al</i>., 32 patients received cladribine for AdvSM<sup><a href="#ref-40">40</a></sup>. The overall response rate was 50%, and the median response durations in ASM and SM-AHN were 30 and 57 months, respectively. However, the median overall survival time was only 2.4 years for ASM. Furthermore, the treatment was not efficient in SM with AHN (particularly associated with myelodysplastic syndrome) and worsened cytopenia. Therefore, cladribine might best be used to treat smoldering forms, chronic MCL and forms associated with myeloproliferative neoplasms, or as a bridge to ASCT transplantation for midostaurin refractory patients.</p><p class="" id=d25892e1936> <b> <i>Allogeneic stem cell transplantation.</i> </b> ASCT remains the only curative treatment for AdvSM and must be considered for all patients. The procedure’s major limitation is eligibility, given the frequency of comorbidities and advanced age in this patient population. Ustun <i>et al</i>. have reported on the largest-yet published series of patients treated with ASCT for AdvSM (n = 57)<sup><a href="#ref-50">50</a></sup>. Around two-thirds of the patients underwent prior myeloablative conditioning, and the 1-year non-relapse mortality rate was 20%. Strikingly, the overall response rate was 70%, and the complete response rate was 28%. The SM and AHN components were both sensitive to ASCT. The 3-year overall survival rate was 57%. It is noteworthy that most of these patients had not received midostaurin, and so one would expect to see better results in midostaurin-treated individuals. A Europe-wide retrospective analysis is ongoing (the European Society for Blood and Marrow Transplantation registry).</p><p class="" id=d25892e1952>At the CEREMAST, we always consider early ASCT for eligible patients with MCL or high-risk AHN (<a href="#f4">Figure 4</a>). For other cases, we typically use next-generation sequencing to screen for S/A/R mutations and decide on the optimal time for ASCT. With regard to the poor outcome for patients bearing these mutations, we plan to perform ASCT within a year of diagnosis (i.e. as soon as patients have achieved the best possible response to treatments such as midostaurin).</p></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d25892e1962>Future perspectives</h2><p class="" id=d25892e1965>Therapeutic progress over the last 10 years (particularly with the emergence of KIT D816V kinase inhibitors) has improved quality of life and survival in patients with mastocytosis. Indeed, these patients have benefited from targeted therapies developed in other diseases, such as cancer and chronic urticaria. Nevertheless, most patients with SM relapse or are incompletely relieved (even after midostaurin treatment), and the symptoms of mastocytosis often decrease their quality of life and significantly affect their social and working lives. Hence, novel therapeutic approaches (alone or in combination with other treatments) are therefore still required, especially for patients with AdvSM who are not eligible for ASCT.</p><p class="" id=d25892e1968>The more active areas of research are targeted therapies, particularly the tyrosine kinase inhibitor avapritinib. No studies are currently investigating chemotherapies or checkpoint inhibitors. Given the overexpression of PD-L1 in SM, anti-PD1 and anti-PDL1 antibodies might be effective with an acceptable safety profile<sup><a href="#ref-51">51</a></sup>. Molecules that target extracellular antigens might be one option (<a href="#f5">Figure 5</a>)<sup><a href="#ref-51">51</a>,<a href="#ref-52">52</a></sup>. Given that tumor MCs from a subset of patients with AdvSM express CD30, brentuximab has been assessed<sup><a href="#ref-53">53</a></sup>. The results were very disappointing; none of the 10 patients responded to treatment<sup><a href="#ref-54">54</a></sup>. Other molecules (AK002, SL-401, and denileukin diftitox) are currently in early phase clinical development. Other treatments targeting signaling pathways are being studied (<a href="#f5">Figure 5</a>); avapritinib or BLU-285 (a new-generation tyrosine kinase inhibitor targeting KIT and its mutants) appears to be the most promising of these. Indeed, the results of a phase I trial (reported at the 2017–2018 American Society of Hematology meeting) highlighted a response in 13 of the 18 treated patients (72%) and, strikingly, included two complete responses. An international phase II study is in progress (the PATHFINDER study, NCT03580655), and the results are particularly expected to assess the adverse events and the long-term response. Lastly, preclinical studies for another tyrosine kinase inhibitor, DCC-2618, have reported interesting results and the drug is currently in phase I study in AdvSM (NCT02571036)<sup><a href="#ref-55">55</a></sup>. In case of confirmation of the efficacy of the two last medications mentioned, a phase III study versus midostaurin seems unlikely regarding the low prevalence of AdvSM. However, that would allow us to optimize the management of our patients according to the safety profile and the patients' comorbidities.</p><a name=f5 class=n-a></a><div class="fig panel clearfix"><a target=_blank href="https://f1000researchdata.s3.amazonaws.com/manuscripts/21341/1e1057d9-4d41-44c2-9059-736d506ee195_figure5.gif"><img alt="1e1057d9-4d41-44c2-9059-736d506ee195_figure5.gif" src="https://f1000researchdata.s3.amazonaws.com/manuscripts/21341/1e1057d9-4d41-44c2-9059-736d506ee195_figure5.gif"></a><div class=caption><h3>Figure 5. Therapeutic perspectives for mastocytosis<sup><a href="#ref-48">48</a>,<a href="#ref-49">49</a></sup>.</h3><p id=d25892e2018>AdvSM, advanced systemic mastocytosis; ISM, indolent systemic mastocytosis; SM, systemic mastocytosis. Based on clinicaltrials.com</p></div></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d25892e2028>Concluding remarks</h2><p class="" id=d25892e2031>Mastocytosis is a rare disease, the classification, physiopathology, and treatment of which have been greatly refined over the last decade. The discovery of <i>KIT</i> mutations has shed light on the physiopathology of mastocytosis and has provided a rationale for targeted treatment. The development of KIT-blocking tyrosine kinase inhibitors has increased overall survival rates among patients with aggressive forms of mastocytosis and has improved quality of life for patients with indolent forms of the disease. However, a better understanding of the role of additional somatic mutations should provide better prognoses, open up new treatment options, and optimize the use of ASCT (currently the only curative treatment). Many questions have yet to be answered, including the cause and physiopathology of spontaneous regression in pediatric forms, the mechanisms by which <i>KIT</i> mutations and other somatic mutations cooperate, the respective roles of the genetic background and environmental factors in disease development, and the heterogeneity of the disease’s signs and symptoms. Answers to these questions would not only provide new treatment options for mastocytosis but also help to resolve a number of problems in oncology and in allergic, neurologic, and psychiatric diseases.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d25892e2043>Abbreviations</h2><p class="" id=d25892e2046>AdvSM, advanced systemic mastocytosis; ASCT, allogeneic stem cell transplantation; ASM, aggressive systemic mastocytosis; BM, bone marrow; CEREMAST, French Reference Center for Mastocytosis; CM, cutaneous mastocytosis; ISM, indolent systemic mastocytosis; MC, mast cell; MCAS, mast cell activation syndrome; MCL, mast cell leukemia; MPCM, maculopapular cutaneous mastocytosis; pegIFN, pegylated interferon; SM, systemic mastocytosis; SM-AHN, systemic mastocytosis with an associated hematologic neoplasm; SSM, smoldering systemic mastocytosis; WHO, World Health Organization</p></div><div id=article1-back class=generated-article-footer><div class=back-section><a name=d25892e2053 class=n-a></a><span class="research-layout prime-recommended-wrapper reference-heading"><span class="f1r-icon icon-79_faculty_recommended_badge red vmiddle default-cursor"></span><span class="prime-red big">F1000 recommended</span></span><h2 class=main-title id=d26308>References</h2><div class="section ref-list"><a name=d25892e2053 class=n-a></a><ul><li><a name=ref-1 class=n-a></a><span class=label>1. </span>&nbsp;<span class=citation><a name=d25892e2060 class=n-a></a>Vaes M, Benghiat FS, Hermine O: Targeted Treatment Options in Mastocytosis. <i>Front Med (Lausanne).</i> 2017; <b>4</b>: 110. <a target=xrefwindow id=d25892e2068 href="http://www.ncbi.nlm.nih.gov/pubmed/28775983">PubMed Abstract </a> | <a target=xrefwindow id=d25892e2071 href="https://doi.org/10.3389/fmed.2017.00110">Publisher Full Text </a> | <a target=xrefwindow id=d25892e2074 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5517467">Free Full Text </a></span></li><li><a name=ref-2 class=n-a></a><span class=label>2. </span>&nbsp;<span class=citation><a name=d25892e2083 class=n-a></a>Pardanani A: How I treat patients with indolent and smoldering mastocytosis (rare conditions but difficult to manage). <i>Blood.</i> 2013; <b>121</b>(16): 3085–94. <a target=xrefwindow id=d25892e2091 href="http://www.ncbi.nlm.nih.gov/pubmed/23426950">PubMed Abstract </a> | <a target=xrefwindow id=d25892e2094 href="https://doi.org/10.1182/blood-2013-01-453183">Publisher Full Text </a></span></li><li><a name=ref-3 class=n-a></a><span class=label>3. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727151697"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d25892e2103 class=n-a></a>Valent P, Akin C, Metcalfe DD: Mastocytosis: 2016 updated WHO classification and novel emerging treatment concepts. <i>Blood.</i> 2017; <b>129</b>(11): 1420–7. <a target=xrefwindow id=d25892e2111 href="http://www.ncbi.nlm.nih.gov/pubmed/28031180">PubMed Abstract </a> | <a target=xrefwindow id=d25892e2114 href="https://doi.org/10.1182/blood-2016-09-731893">Publisher Full Text </a> | <a target=xrefwindow id=d25892e2117 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5356454">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727151697">F1000 Recommendation</a></span></li><li><a name=ref-4 class=n-a></a><span class=label>4. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732011973"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d25892e2130 class=n-a></a>Scherber RM, Borate U: How we diagnose and treat systemic mastocytosis in adults. <i>Br J Haematol.</i> 2018; <b>180</b>(1): 11–23. <a target=xrefwindow id=d25892e2138 href="http://www.ncbi.nlm.nih.gov/pubmed/29048112">PubMed Abstract </a> | <a target=xrefwindow id=d25892e2141 href="https://doi.org/10.1111/bjh.14967">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732011973">F1000 Recommendation</a></span></li><li><a name=ref-5 class=n-a></a><span class=label>5. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733590638"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d25892e2154 class=n-a></a>Arock M, Wedeh G, Hoermann G, <i> et al.</i>: Preclinical human models and emerging therapeutics for advanced systemic mastocytosis. <i>Haematologica.</i> 2018; <b>103</b>(11): 1760–71. <a target=xrefwindow id=d25892e2165 href="http://www.ncbi.nlm.nih.gov/pubmed/29976735">PubMed Abstract </a> | <a target=xrefwindow id=d25892e2168 href="https://doi.org/10.3324/haematol.2018.195867">Publisher Full Text </a> | <a target=xrefwindow id=d25892e2172 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6278969">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733590638">F1000 Recommendation</a></span></li><li><a name=ref-6 class=n-a></a><span class=label>6. </span>&nbsp;<span class=citation><a name=d25892e2186 class=n-a></a>Schwaab J, Schnittger S, Sotlar K, <i> et al.</i>: Comprehensive mutational profiling in advanced systemic mastocytosis. <i>Blood.</i> 2013; <b>122</b>(14): 2460–6. <a target=xrefwindow id=d25892e2197 href="http://www.ncbi.nlm.nih.gov/pubmed/23958953">PubMed Abstract </a> | <a target=xrefwindow id=d25892e2200 href="https://doi.org/10.1182/blood-2013-04-496448">Publisher Full Text </a></span></li><li><a name=ref-7 class=n-a></a><span class=label>7. </span>&nbsp;<span class=citation><a name=d25892e2209 class=n-a></a>Yavuz AS, Lipsky PE, Yavuz S, <i> et al.</i>: Evidence for the involvement of a hematopoietic progenitor cell in systemic mastocytosis from single-cell analysis of mutations in the c-kit gene. <i>Blood.</i> 2002; <b>100</b>(2): 661–5. <a target=xrefwindow id=d25892e2220 href="http://www.ncbi.nlm.nih.gov/pubmed/12091362">PubMed Abstract </a> | <a target=xrefwindow id=d25892e2223 href="https://doi.org/10.1182/blood-2002-01-0203">Publisher Full Text </a></span></li><li><a name=ref-8 class=n-a></a><span class=label>8. </span>&nbsp;<span class=citation><a name=d25892e2232 class=n-a></a>Pardanani A: Systemic mastocytosis in adults: 2017 update on diagnosis, risk stratification and management. <i>Am J Hematol.</i> 2016; <b>91</b>(11): 1146–59. <a target=xrefwindow id=d25892e2240 href="http://www.ncbi.nlm.nih.gov/pubmed/27762455">PubMed Abstract </a> | <a target=xrefwindow id=d25892e2243 href="https://doi.org/10.1002/ajh.24553">Publisher Full Text </a></span></li><li><a name=ref-9 class=n-a></a><span class=label>9. </span>&nbsp;<span class=citation><a name=d25892e2252 class=n-a></a>Valent P, Akin C, Bonadonna P, <i> et al.</i>: Proposed Diagnostic Algorithm for Patients with Suspected Mast Cell Activation Syndrome. <i>J Allergy Clin Immunol Pract.</i> 2019; <b>7</b>(4): 1125–1133.e1. <a target=xrefwindow id=d25892e2263 href="http://www.ncbi.nlm.nih.gov/pubmed/30737190">PubMed Abstract </a> | <a target=xrefwindow id=d25892e2266 href="https://doi.org/10.1016/j.jaip.2019.01.006">Publisher Full Text </a> | <a target=xrefwindow id=d25892e2270 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6643056">Free Full Text </a></span></li><li><a name=ref-10 class=n-a></a><span class=label>10. </span>&nbsp;<span class=citation><a name=d25892e2279 class=n-a></a>Alvarez-Twose I, González-de-Olano D, Sánchez-Muñoz L, <i> et al.</i>: Validation of the REMA score for predicting mast cell clonality and systemic mastocytosis in patients with systemic mast cell activation symptoms. <i>Int Arch Allergy Immunol.</i> 2012; <b>157</b>(3): 275–80. <a target=xrefwindow id=d25892e2290 href="http://www.ncbi.nlm.nih.gov/pubmed/22042301">PubMed Abstract </a> | <a target=xrefwindow id=d25892e2293 href="https://doi.org/10.1159/000329856">Publisher Full Text </a></span></li><li><a name=ref-11 class=n-a></a><span class=label>11. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727734869"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d25892e2302 class=n-a></a>Carter MC, Desai A, Komarow HD, <i> et al.</i>: A distinct biomolecular profile identifies monoclonal mast cell disorders in patients with idiopathic anaphylaxis. <i>J Allergy Clin Immunol.</i> 2018; <b>141</b>(1): 180–188.e3. <a target=xrefwindow id=d25892e2313 href="http://www.ncbi.nlm.nih.gov/pubmed/28629749">PubMed Abstract </a> | <a target=xrefwindow id=d25892e2316 href="https://doi.org/10.1016/j.jaci.2017.05.036">Publisher Full Text </a> | <a target=xrefwindow id=d25892e2320 href="http://www.ncbi.nlm.nih.gov/pmc/articles/6311988">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727734869">F1000 Recommendation</a></span></li><li><a name=ref-12 class=n-a></a><span class=label>12. </span>&nbsp;<span class=citation><a name=d25892e2334 class=n-a></a>Arock M, Akin C, Hermine O, <i> et al.</i>: Current treatment options in patients with mastocytosis: Status in 2015 and future perspectives. <i>Eur J Haematol.</i> 2015; <b>94</b>(6): 474–90. <a target=xrefwindow id=d25892e2345 href="http://www.ncbi.nlm.nih.gov/pubmed/25753531">PubMed Abstract </a> | <a target=xrefwindow id=d25892e2348 href="https://doi.org/10.1111/ejh.12544">Publisher Full Text </a></span></li><li><a name=ref-13 class=n-a></a><span class=label>13. </span>&nbsp;<span class=citation><a name=d25892e2357 class=n-a></a>Hartmann K, Escribano L, Grattan C, <i> et al.</i>: Cutaneous manifestations in patients with mastocytosis: Consensus report of the European Competence Network on Mastocytosis; the American Academy of Allergy, Asthma &amp; Immunology; and the European Academy of Allergology and Clinical Immunology. <i>J Allergy Clin Immunol.</i> 2016; <b>137</b>(1): 35–45. <a target=xrefwindow id=d25892e2368 href="http://www.ncbi.nlm.nih.gov/pubmed/26476479">PubMed Abstract </a> | <a target=xrefwindow id=d25892e2371 href="https://doi.org/10.1016/j.jaci.2015.08.034">Publisher Full Text </a></span></li><li><a name=ref-14 class=n-a></a><span class=label>14. </span>&nbsp;<span class=citation><a name=d25892e2380 class=n-a></a>Wiechers T, Rabenhorst A, Schick T, <i> et al.</i>: Large maculopapular cutaneous lesions are associated with favorable outcome in childhood-onset mastocytosis. <i>J Allergy Clin Immunol.</i> 2015; <b>136</b>(6): 1581–1590.e3. <a target=xrefwindow id=d25892e2391 href="http://www.ncbi.nlm.nih.gov/pubmed/26152315">PubMed Abstract </a> | <a target=xrefwindow id=d25892e2394 href="https://doi.org/10.1016/j.jaci.2015.05.034">Publisher Full Text </a></span></li><li><a name=ref-15 class=n-a></a><span class=label>15. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727191509"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d25892e2403 class=n-a></a>Lortholary O, Chandesris MO, Bulai Livideanu C, <i> et al.</i>: Masitinib for treatment of severely symptomatic indolent systemic mastocytosis: A randomised, placebo-controlled, phase 3 study. <i>Lancet.</i> 2017; <b>389</b>(10069): 612–20. <a target=xrefwindow id=d25892e2414 href="http://www.ncbi.nlm.nih.gov/pubmed/28069279">PubMed Abstract </a> | <a target=xrefwindow id=d25892e2417 href="https://doi.org/10.1016/S0140-6736(16)31403-9">Publisher Full Text </a> | <a target=xrefwindow id=d25892e2421 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5985971">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727191509">F1000 Recommendation</a></span></li><li><a name=ref-16 class=n-a></a><span class=label>16. </span>&nbsp;<span class=citation><a name=d25892e2434 class=n-a></a>Valent P, Horny HP, Escribano L, <i> et al.</i>: Diagnostic criteria and classification of mastocytosis: A consensus proposal. <i>Leuk Res.</i> 2001; <b>25</b>(7): 603–25. <a target=xrefwindow id=d25892e2445 href="http://www.ncbi.nlm.nih.gov/pubmed/11377686">PubMed Abstract </a> | <a target=xrefwindow id=d25892e2448 href="https://doi.org/10.1016/s0145-2126(01)00038-8">Publisher Full Text </a></span></li><li><a name=ref-17 class=n-a></a><span class=label>17. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733313755"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d25892e2457 class=n-a></a>Gentek R, Ghigo C, Hoeffel G, <i> et al.</i>: Hemogenic Endothelial Fate Mapping Reveals Dual Developmental Origin of Mast Cells. <i>Immunity.</i> 2018; <b>48</b>(6): 1160–1171.e5. <a target=xrefwindow id=d25892e2468 href="http://www.ncbi.nlm.nih.gov/pubmed/29858009">PubMed Abstract </a> | <a target=xrefwindow id=d25892e2471 href="https://doi.org/10.1016/j.immuni.2018.04.025">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733313755">F1000 Recommendation</a></span></li><li><a name=ref-18 class=n-a></a><span class=label>18. </span>&nbsp;<span class=citation><a name=d25892e2485 class=n-a></a>Longley BJ Jr, Metcalfe DD, Tharp M, <i> et al.</i>: Activating and dominant inactivating c-KIT catalytic domain mutations in distinct clinical forms of human mastocytosis. <i>Proc Natl Acad Sci U S A.</i> 1999; <b>96</b>(4): 1609–14. <a target=xrefwindow id=d25892e2496 href="http://www.ncbi.nlm.nih.gov/pubmed/9990072">PubMed Abstract </a> | <a target=xrefwindow id=d25892e2499 href="https://doi.org/10.1073/pnas.96.4.1609">Publisher Full Text </a> | <a target=xrefwindow id=d25892e2503 href="http://www.ncbi.nlm.nih.gov/pmc/articles/15534">Free Full Text </a></span></li><li><a name=ref-19 class=n-a></a><span class=label>19. </span>&nbsp;<span class=citation><a name=d25892e2512 class=n-a></a>Bodemer C, Hermine O, Palmérini F, <i> et al.</i>: Pediatric mastocytosis is a clonal disease associated with D816V and other activating c-KIT mutations. <i>J Invest Dermatol.</i> 2010; <b>130</b>(3): 804–15. <a target=xrefwindow id=d25892e2523 href="http://www.ncbi.nlm.nih.gov/pubmed/19865100">PubMed Abstract </a> | <a target=xrefwindow id=d25892e2526 href="https://doi.org/10.1038/jid.2009.281">Publisher Full Text </a></span></li><li><a name=ref-20 class=n-a></a><span class=label>20. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1022182"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d25892e2535 class=n-a></a>Zappulla JP, Dubreuil P, Desbois S, <i> et al.</i>: Mastocytosis in mice expressing human Kit receptor with the activating Asp816Val mutation. <i>J Exp Med.</i> 2005; <b>202</b>(12): 1635–41. <a target=xrefwindow id=d25892e2546 href="http://www.ncbi.nlm.nih.gov/pubmed/16352739">PubMed Abstract </a> | <a target=xrefwindow id=d25892e2549 href="https://doi.org/10.1084/jem.20050807">Publisher Full Text </a> | <a target=xrefwindow id=d25892e2553 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2212965">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1022182">F1000 Recommendation</a></span></li><li><a name=ref-21 class=n-a></a><span class=label>21. </span>&nbsp;<span class=citation><a name=d25892e2566 class=n-a></a>Hartmann K, Wardelmann E, Ma Y, <i> et al.</i>: Novel Germline Mutation of KIT Associated With Familial Gastrointestinal Stromal Tumors and Mastocytosis. <i>Gastroenterology.</i> 2005; <b>129</b>(3): 1042–6. <a target=xrefwindow id=d25892e2577 href="http://www.ncbi.nlm.nih.gov/pubmed/16143141">PubMed Abstract </a> | <a target=xrefwindow id=d25892e2580 href="https://doi.org/10.1053/j.gastro.2005.06.060">Publisher Full Text </a></span></li><li><a name=ref-22 class=n-a></a><span class=label>22. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/12621"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d25892e2589 class=n-a></a>Zhang LY, Smith ML, Schultheis B, <i> et al.</i>: A novel K509I mutation of KIT identified in familial mastocytosis-<i>in vitro</i> and <i>in vivo</i> responsiveness to imatinib therapy. <i>Leuk Res.</i> 2006; <b>30</b>(4): 373–8. <a target=xrefwindow id=d25892e2607 href="http://www.ncbi.nlm.nih.gov/pubmed/16183119">PubMed Abstract </a> | <a target=xrefwindow id=d25892e2610 href="https://doi.org/10.1016/j.leukres.2005.08.015">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/12621">F1000 Recommendation</a></span></li><li><a name=ref-23 class=n-a></a><span class=label>23. </span>&nbsp;<span class=citation><a name=d25892e2622 class=n-a></a>Speight RA, Nicolle A, Needham SJ, <i> et al.</i>: Rare, Germline Mutation of KIT With Imatinib-Resistant Multiple GI Stromal Tumors and Mastocytosis. <i>J Clin Oncol.</i> 2013; <b>31</b>(16): e245–e247. <a target=xrefwindow id=d25892e2633 href="http://www.ncbi.nlm.nih.gov/pubmed/23610110">PubMed Abstract </a> | <a target=xrefwindow id=d25892e2636 href="https://doi.org/10.1200/JCO.2012.42.0133">Publisher Full Text </a></span></li><li><a name=ref-24 class=n-a></a><span class=label>24. </span>&nbsp;<span class=citation><a name=d25892e2646 class=n-a></a>Chan EC, Bai Y, Kirshenbaum AS, <i> et al.</i>: Mastocytosis associated with a rare germline KIT K509I mutation displays a well-differentiated mast cell phenotype. <i>J Allergy Clin Immunol.</i> 2014; <b>134</b>(1): 178–187.e1. <a target=xrefwindow id=d25892e2657 href="http://www.ncbi.nlm.nih.gov/pubmed/24582309">PubMed Abstract </a> | <a target=xrefwindow id=d25892e2660 href="https://doi.org/10.1016/j.jaci.2013.12.1090">Publisher Full Text </a> | <a target=xrefwindow id=d25892e2664 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4125511">Free Full Text </a></span></li><li><a name=ref-25 class=n-a></a><span class=label>25. </span>&nbsp;<span class=citation><a name=d25892e2673 class=n-a></a>Tang X, Boxer M, Drummond A, <i> et al.</i>: A germline mutation in KIT in familial diffuse cutaneous mastocytosis. <i>J Med Genet.</i> 2004; <b>41</b>(6): e88. <a target=xrefwindow id=d25892e2684 href="http://www.ncbi.nlm.nih.gov/pubmed/15173254">PubMed Abstract </a> | <a target=xrefwindow id=d25892e2687 href="https://doi.org/10.1136/jmg.2003.015156">Publisher Full Text </a> | <a target=xrefwindow id=d25892e2691 href="http://www.ncbi.nlm.nih.gov/pmc/articles/1735799">Free Full Text </a></span></li><li><a name=ref-26 class=n-a></a><span class=label>26. </span>&nbsp;<span class=citation><a name=d25892e2700 class=n-a></a>Foster R, Byrnes E, Meldrum C, <i> et al.</i>: Association of paediatric mastocytosis with a polymorphism resulting in an amino acid substitution (M541L) in the transmembrane domain of c-KIT. <i>Br J Dermatol.</i> 2008; <b>159</b>(5): 1160–9. <a target=xrefwindow id=d25892e2711 href="http://www.ncbi.nlm.nih.gov/pubmed/18795925">PubMed Abstract </a> | <a target=xrefwindow id=d25892e2714 href="https://doi.org/10.1111/j.1365-2133.2008.08827.x">Publisher Full Text </a></span></li><li><a name=ref-27 class=n-a></a><span class=label>27. </span>&nbsp;<span class=citation><a name=d25892e2723 class=n-a></a>Beghini A, Tibiletti M, Roversi G, <i> et al.</i>: Germline mutation in the juxtamembrane domain of the kit gene in a family with gastrointestinal stromal tumors and urticaria pigmentosa. <i>Cancer.</i> 2001; <b>92</b>(3): 657–62. <a target=xrefwindow id=d25892e2734 href="http://www.ncbi.nlm.nih.gov/pubmed/11505412">PubMed Abstract </a> | <a target="xrefwindow" id="d25892e2737" href="https://doi.org/10.1002/1097-0142(20010801)92:3<657::aid-cncr1367&gt;3.0.co;2-d">Publisher Full Text </a></span></li><li><a name=ref-28 class=n-a></a><span class=label>28. </span>&nbsp;<span class=citation><a name=d25892e2746 class=n-a></a>Li FP, Fletcher JA, Heinrich MC, <i> et al.</i>: Familial gastrointestinal stromal tumor syndrome: Phenotypic and molecular features in a kindred. <i>J Clin Oncol.</i> 2005; <b>23</b>(12): 2735–43. <a target=xrefwindow id=d25892e2757 href="http://www.ncbi.nlm.nih.gov/pubmed/15837988">PubMed Abstract </a> | <a target=xrefwindow id=d25892e2760 href="https://doi.org/10.1200/JCO.2005.06.009">Publisher Full Text </a></span></li><li><a name=ref-29 class=n-a></a><span class=label>29. </span>&nbsp;<span class=citation><a name=d25892e2769 class=n-a></a>Pollard WL, Beachkofsky TM, Kobayashi TT: Novel R634W c-kit Mutation Identified in Familial Mastocytosis. <i>Pediatr Dermatol.</i> 2015; <b>32</b>(2): 267–70. <a target=xrefwindow id=d25892e2777 href="http://www.ncbi.nlm.nih.gov/pubmed/25243845">PubMed Abstract </a> | <a target=xrefwindow id=d25892e2780 href="https://doi.org/10.1111/pde.12381">Publisher Full Text </a></span></li><li><a name=ref-30 class=n-a></a><span class=label>30. </span>&nbsp;<span class=citation><a name=d25892e2790 class=n-a></a>Wasag B, Niedoszytko M, Piskorz A, <i> et al.</i>: Novel, activating KIT-N822I mutation in familial cutaneous mastocytosis. <i>Exp Hematol.</i> 2011; <b>39</b>(8): 859–65.e2. <a target=xrefwindow id=d25892e2801 href="http://www.ncbi.nlm.nih.gov/pubmed/21689725">PubMed Abstract </a> | <a target=xrefwindow id=d25892e2804 href="https://doi.org/10.1016/j.exphem.2011.05.009">Publisher Full Text </a></span></li><li><a name=ref-31 class=n-a></a><span class=label>31. </span>&nbsp;<span class=citation><a name=d25892e2813 class=n-a></a>de Melo Campos P, Machado-Neto JA, Scopim-Ribeiro R, <i> et al.</i>: Familial systemic mastocytosis with germline KIT K509I mutation is sensitive to treatment with imatinib, dasatinib and PKC412. <i>Leuk Res.</i> 2014; <b>38</b>(10): 1245–51. <a target=xrefwindow id=d25892e2824 href="http://www.ncbi.nlm.nih.gov/pubmed/25139846">PubMed Abstract </a> | <a target=xrefwindow id=d25892e2827 href="https://doi.org/10.1016/j.leukres.2014.07.010">Publisher Full Text </a></span></li><li><a name=ref-32 class=n-a></a><span class=label>32. </span>&nbsp;<span class=citation><a name=d25892e2836 class=n-a></a>Mayerhofer M, Gleixner KV, Hoelbl A, <i> et al.</i>: Unique effects of KIT D816V in BaF3 cells: induction of cluster formation, histamine synthesis, and early mast cell differentiation antigens. <i>J Immunol.</i> 2008; <b>180</b>(8): 5466–76. <a target=xrefwindow id=d25892e2847 href="http://www.ncbi.nlm.nih.gov/pubmed/18390729">PubMed Abstract </a> | <a target=xrefwindow id=d25892e2850 href="https://doi.org/10.4049/jimmunol.180.8.5466">Publisher Full Text </a> | <a target=xrefwindow id=d25892e2854 href="http://www.ncbi.nlm.nih.gov/pmc/articles/2976849">Free Full Text </a></span></li><li><a name=ref-33 class=n-a></a><span class=label>33. </span>&nbsp;<span class=citation><a name=d25892e2863 class=n-a></a>Jawhar M, Schwaab J, Schnittger S, <i> et al.</i>: Molecular profiling of myeloid progenitor cells in multi-mutated advanced systemic mastocytosis identifies KIT D816V as a distinct and late event. <i>Leukemia.</i> 2015; <b>29</b>(5): 1115–22. <a target=xrefwindow id=d25892e2874 href="http://www.ncbi.nlm.nih.gov/pubmed/25567135">PubMed Abstract </a> | <a target=xrefwindow id=d25892e2877 href="https://doi.org/10.1038/leu.2015.4">Publisher Full Text </a></span></li><li><a name=ref-34 class=n-a></a><span class=label>34. </span>&nbsp;<span class=citation><a name=d25892e2886 class=n-a></a>Jawhar M, Schwaab J, Schnittger S, <i> et al.</i>: Additional mutations in SRSF2, ASXL1 and/or RUNX1 identify a high-risk group of patients with KIT D816V<sup>+</sup> advanced systemic mastocytosis. <i>Leukemia.</i> 2016; <b>30</b>(1): 136–43. <a target=xrefwindow id=d25892e2900 href="http://www.ncbi.nlm.nih.gov/pubmed/26464169">PubMed Abstract </a> | <a target=xrefwindow id=d25892e2904 href="https://doi.org/10.1038/leu.2015.284">Publisher Full Text </a></span></li><li><a name=ref-35 class=n-a></a><span class=label>35. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/733167690"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d25892e2913 class=n-a></a>Patnaik MM, Vallapureddy Rangit, Lasho TL, <i> et al.</i>: A comparison of clinical and molecular characteristics of patients with systemic mastocytosis with chronic myelomonocytic leukemia to CMML alone. <i>Leukemia.</i> 2018; <b>32</b>(8): 1850–6. <a target=xrefwindow id=d25892e2924 href="http://www.ncbi.nlm.nih.gov/pubmed/29712989">PubMed Abstract </a> | <a target=xrefwindow id=d25892e2927 href="https://doi.org/10.1038/s41375-018-0121-1">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/733167690">F1000 Recommendation</a></span></li><li><a name=ref-36 class=n-a></a><span class=label>36. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/1160272"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d25892e2941 class=n-a></a>Lim KH, Tefferi A, Lasho TL, <i> et al.</i>: Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors. <i>Blood.</i> 2009; <b>113</b>(23): 5727–36. <a target=xrefwindow id=d25892e2952 href="http://www.ncbi.nlm.nih.gov/pubmed/19363219">PubMed Abstract </a> | <a target=xrefwindow id=d25892e2955 href="https://doi.org/10.1182/blood-2009-02-205237">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/1160272">F1000 Recommendation</a></span></li><li><a name=ref-37 class=n-a></a><span class=label>37. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727846464"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d25892e2968 class=n-a></a>Sturm GJ, Varga EM, Roberts G, <i> et al.</i>: EAACI guidelines on allergen immunotherapy: Hymenoptera venom allergy. <i>Allergy.</i> 2018; <b>73</b>(4): 744–64. <a target=xrefwindow id=d25892e2979 href="http://www.ncbi.nlm.nih.gov/pubmed/28748641">PubMed Abstract </a> | <a target=xrefwindow id=d25892e2982 href="https://doi.org/10.1111/all.13262">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727846464">F1000 Recommendation</a></span></li><li><a name=ref-38 class=n-a></a><span class=label>38. </span>&nbsp;<span class=citation><a name=d25892e2995 class=n-a></a>Dewachter P, Castells MC, Hepner DL, <i> et al.</i>: Perioperative management of patients with mastocytosis. <i>Anesthesiology.</i> 2014; <b>120</b>(3): 753–9. <a target=xrefwindow id=d25892e3006 href="http://www.ncbi.nlm.nih.gov/pubmed/24135579">PubMed Abstract </a> | <a target=xrefwindow id=d25892e3009 href="https://doi.org/10.1097/ALN.0000000000000031">Publisher Full Text </a></span></li><li><a name=ref-39 class=n-a></a><span class=label>39. </span>&nbsp;<span class=citation><a name=d25892e3018 class=n-a></a>Niesters M, Martini C, Dahan A: Ketamine for chronic pain: risks and benefits. <i>Br J Clin Pharmacol.</i> 2014; <b>77</b>(2): 357–67. <a target=xrefwindow id=d25892e3026 href="http://www.ncbi.nlm.nih.gov/pubmed/23432384">PubMed Abstract </a> | <a target=xrefwindow id=d25892e3029 href="https://doi.org/10.1111/bcp.12094">Publisher Full Text </a> | <a target=xrefwindow id=d25892e3032 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4014022">Free Full Text </a></span></li><li><a name=ref-40 class=n-a></a><span class=label>40. </span>&nbsp;<span class=citation><a name=d25892e3041 class=n-a></a>Barete S, Lortholary O, Damaj G, <i> et al.</i>: Long-term efficacy and safety of cladribine (2-CdA) in adult patients with mastocytosis. <i>Blood.</i> 2015; <b>126</b>(6): 1009–16; quiz 1050. <a target=xrefwindow id=d25892e3052 href="http://www.ncbi.nlm.nih.gov/pubmed/26002962">PubMed Abstract </a> | <a target=xrefwindow id=d25892e3055 href="https://doi.org/10.1182/blood-2014-12-614743">Publisher Full Text </a></span></li><li><a name=ref-41 class=n-a></a><span class=label>41. </span>&nbsp;<span class=citation><a name=d25892e3064 class=n-a></a>Lim KH, Pardanani A, Butterfield JH, <i> et al.</i>: Cytoreductive therapy in 108 adults with systemic mastocytosis: Outcome analysis and response prediction during treatment with interferon-alpha, hydroxyurea, imatinib mesylate or 2-chlorodeoxyadenosine. <i>Am J Hematol.</i> 2009; <b>84</b>(12): 790–4. <a target=xrefwindow id=d25892e3075 href="http://www.ncbi.nlm.nih.gov/pubmed/19890907">PubMed Abstract </a> | <a target=xrefwindow id=d25892e3078 href="https://doi.org/10.1002/ajh.21561">Publisher Full Text </a></span></li><li><a name=ref-42 class=n-a></a><span class=label>42. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/727760766"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d25892e3088 class=n-a></a>Broesby-Olsen S, Vestergaard H, Mortz CG, <i> et al.</i>: Omalizumab prevents anaphylaxis and improves symptoms in systemic mastocytosis: Efficacy and safety observations. <i>Allergy.</i> 2018; <b>73</b>(1): 230–8. <a target=xrefwindow id=d25892e3099 href="http://www.ncbi.nlm.nih.gov/pubmed/28662309">PubMed Abstract </a> | <a target=xrefwindow id=d25892e3102 href="https://doi.org/10.1111/all.13237">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/727760766">F1000 Recommendation</a></span></li><li><a name=ref-43 class=n-a></a><span class=label>43. </span>&nbsp;<span class=citation><a name=d25892e3115 class=n-a></a>Lemal R, Fouquet G, Terriou L, <i> et al.</i>: Omalizumab Therapy for Mast Cell-Mediator Symptoms in Patients with ISM, CM, MMAS, and MCAS. <i>J Allergy Clin Immunol Pract.</i> 2019; <b>7</b>(7): 2387–2395.e3. <a target=xrefwindow id=d25892e3126 href="http://www.ncbi.nlm.nih.gov/pubmed/30954641">PubMed Abstract </a> | <a target=xrefwindow id=d25892e3129 href="https://doi.org/10.1016/j.jaip.2019.03.039">Publisher Full Text </a></span></li><li><a name=ref-44 class=n-a></a><span class=label>44. </span>&nbsp;<span class=citation><a name=d25892e3138 class=n-a></a>Vega-Ruiz A, Cortes JE, Sever M, <i> et al.</i>: Phase II study of imatinib mesylate as therapy for patients with systemic mastocytosis. <i>Leuk Res.</i> 2009; <b>33</b>(11): 1481–4. <a target=xrefwindow id=d25892e3149 href="http://www.ncbi.nlm.nih.gov/pubmed/19193436">PubMed Abstract </a> | <a target=xrefwindow id=d25892e3152 href="https://doi.org/10.1016/j.leukres.2008.12.020">Publisher Full Text </a> | <a target=xrefwindow id=d25892e3156 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4184059">Free Full Text </a></span></li><li><a name=ref-45 class=n-a></a><span class=label>45. </span>&nbsp;<span class=citation><a name=d25892e3165 class=n-a></a>Verstovsek S, Tefferi A, Cortes J, <i> et al.</i>: Phase II study of dasatinib in Philadelphia chromosome-negative acute and chronic myeloid diseases, including systemic mastocytosis. <i>Clin Cancer Res.</i> 2008; <b>14</b>(12): 3906–15. <a target=xrefwindow id=d25892e3176 href="http://www.ncbi.nlm.nih.gov/pubmed/18559612">PubMed Abstract </a> | <a target=xrefwindow id=d25892e3179 href="https://doi.org/10.1158/1078-0432.CCR-08-0366">Publisher Full Text </a> | <a target=xrefwindow id=d25892e3183 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5018899">Free Full Text </a></span></li><li><a name=ref-46 class=n-a></a><span class=label>46. </span>&nbsp;<span class=citation><a name=d25892e3192 class=n-a></a>Gabillot-Carré M, Lepelletier Y, Humbert M, <i> et al.</i>: Rapamycin inhibits growth and survival of D816V-mutated c-kit mast cells. <i>Blood.</i> 2006; <b>108</b>(3): 1065–72. <a target=xrefwindow id=d25892e3203 href="http://www.ncbi.nlm.nih.gov/pubmed/16597595">PubMed Abstract </a> | <a target=xrefwindow id=d25892e3206 href="https://doi.org/10.1182/blood-2005-06-2433">Publisher Full Text </a></span></li><li><a name=ref-47 class=n-a></a><span class=label>47. </span>&nbsp;<span class=citation><a name=d25892e3215 class=n-a></a>Kluin-Nelemans HC, Oldhoff JM, van Doormaal JJ, <i> et al.</i>: Cladribine therapy for systemic mastocytosis. <i>Blood.</i> 2003; <b>102</b>(13): 4270–6. <a target=xrefwindow id=d25892e3226 href="http://www.ncbi.nlm.nih.gov/pubmed/12933573">PubMed Abstract </a> | <a target=xrefwindow id=d25892e3229 href="https://doi.org/10.1182/blood-2003-05-1699">Publisher Full Text </a></span></li><li><a name=ref-48 class=n-a></a><span class=label>48. </span>&nbsp;<span class=citation><a name=d25892e3239 class=n-a></a>Pagano L, Valentini CG, Caira M, <i> et al.</i>: Advanced mast cell disease: an Italian Hematological Multicenter experience. <i>Int J Hematol.</i> 2008; <b>88</b>(5): 483–8. <a target=xrefwindow id=d25892e3250 href="http://www.ncbi.nlm.nih.gov/pubmed/19034614">PubMed Abstract </a> | <a target=xrefwindow id=d25892e3253 href="https://doi.org/10.1007/s12185-008-0166-4">Publisher Full Text </a></span></li><li><a name=ref-49 class=n-a></a><span class=label>49. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/726470483"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d25892e3262 class=n-a></a>Gotlib J, Kluin-Nelemans HC, George TI, <i> et al.</i>: Efficacy and Safety of Midostaurin in Advanced Systemic Mastocytosis. <i>N Engl J Med.</i> 2016; <b>374</b>(26): 2530–41. <a target=xrefwindow id=d25892e3273 href="http://www.ncbi.nlm.nih.gov/pubmed/27355533">PubMed Abstract </a> | <a target=xrefwindow id=d25892e3276 href="https://doi.org/10.1056/NEJMoa1513098">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/726470483">F1000 Recommendation</a></span></li><li><a name=ref-50 class=n-a></a><span class=label>50. </span>&nbsp;<span class=citation><a name=d25892e3289 class=n-a></a>Ustun C, Reiter A, Scott BL, <i> et al.</i>: Hematopoietic stem-cell transplantation for advanced systemic mastocytosis. <i>J Clin Oncol.</i> 2014; <b>32</b>(29): 3264–74. <a target=xrefwindow id=d25892e3300 href="http://www.ncbi.nlm.nih.gov/pubmed/25154823">PubMed Abstract </a> | <a target=xrefwindow id=d25892e3303 href="https://doi.org/10.1200/JCO.2014.55.2018">Publisher Full Text </a> | <a target=xrefwindow id=d25892e3307 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4876356">Free Full Text </a></span></li><li><a name=ref-51 class=n-a></a><span class=label>51. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732713970"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d25892e3316 class=n-a></a>Hatch EW, Geeze MB, Martin C, <i> et al.</i>: Variability of PD-L1 expression in mastocytosis. <i>Blood Adv.</i> 2018; <b>2</b>(3): 189–99. <a target=xrefwindow id=d25892e3327 href="http://www.ncbi.nlm.nih.gov/pubmed/29378725">PubMed Abstract </a> | <a target=xrefwindow id=d25892e3330 href="https://doi.org/10.1182/bloodadvances.2017011551">Publisher Full Text </a> | <a target=xrefwindow id=d25892e3334 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5812326">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732713970">F1000 Recommendation</a></span></li><li><a name=ref-52 class=n-a></a><span class=label>52. </span>&nbsp;<span class=citation><a name=d25892e3347 class=n-a></a>Alvarez-Twose I, Martínez-Barranco P, Gotlib J, <i> et al.</i>: Complete response to gemtuzumab ozogamicin in a patient with refractory mast cell leukemia. <i>Leukemia.</i> 2016; <b>30</b>(8): 1753–6. <a target=xrefwindow id=d25892e3358 href="http://www.ncbi.nlm.nih.gov/pubmed/26876592">PubMed Abstract </a> | <a target=xrefwindow id=d25892e3361 href="https://doi.org/10.1038/leu.2016.30">Publisher Full Text </a></span></li><li><a name=ref-53 class=n-a></a><span class=label>53. </span>&nbsp;<span class=citation><a name=d25892e3370 class=n-a></a>Blatt K, Cerny-Reiterer S, Schwaab J, <i> et al.</i>: Identification of the Ki-1 antigen (CD30) as a novel therapeutic target in systemic mastocytosis. <i>Blood.</i> 2015; <b>126</b>(26): 2832–41. <a target=xrefwindow id=d25892e3381 href="http://www.ncbi.nlm.nih.gov/pubmed/26486787">PubMed Abstract </a> | <a target=xrefwindow id=d25892e3384 href="https://doi.org/10.1182/blood-2015-03-637728">Publisher Full Text </a> | <a target=xrefwindow id=d25892e3388 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4692143">Free Full Text </a></span></li><li><a name=ref-54 class=n-a></a><span class=label>54. </span>&nbsp;<span class=citation><a name=d25892e3398 class=n-a></a>Baird JH, <i> et al.</i>: Phase 2 Study of Brentuximab Vedotin in Patients with Advanced Systemic Mastocytosis. <i>Blood.</i> 2017; <b>130</b>: 2909–2909.</span></li><li><a name=ref-55 class=n-a></a><span class=label>55. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="https://f1000.com/prime/732656326"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d25892e3416 class=n-a></a>Schneeweiss M, Peter B, Bibi S, <i> et al.</i>: The KIT and PDGFRA switch-control inhibitor DCC-2618 blocks growth and survival of multiple neoplastic cell types in advanced mastocytosis. <i>Haematologica.</i> 2018; <b>103</b>(5): 799–809. <a target=xrefwindow id=d25892e3427 href="http://www.ncbi.nlm.nih.gov/pubmed/29439183">PubMed Abstract </a> | <a target=xrefwindow id=d25892e3430 href="https://doi.org/10.3324/haematol.2017.179895">Publisher Full Text </a> | <a target=xrefwindow id=d25892e3434 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5927976">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="https://f1000.com/prime/732656326">F1000 Recommendation</a></span></li></ul></div></div></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 22 Nov 2019</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/8-1961/v1&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/8-1961/v1&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> <div class="f1r-article-mobile margin-bottom-30"> <div class=contracted-details> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> <sup>1</sup> French Reference Center for Mastocytosis (CEREMAST), Necker Children's Hospital, APHP, Paris, France<br/> <sup>2</sup> Department of Hematology, Gustave Roussy Institute, Paris-Saclay University, Villejuif, France<br/> <sup>3</sup> Imagine Institute, Paris University, INSERM U 1183, Paris, France<br/> <sup>4</sup> Centre de Recherche en Canc&eacute;rologie de Marseille, Inserm U1068, Marseille, France<br/> <sup>5</sup> Department of Hematology, Necker Children's Hospital, APHP, Paris, France<br/> <sup>6</sup> Department of Dermatology, Necker Children's Hospital, APHP, Paris, France<br/> <p> <div class=margin-bottom> Julien Rossignol <br/> <span>Roles: </span> Conceptualization, Writing – Original Draft Preparation </div> <div class=margin-bottom> Laura Polivka <br/> <span>Roles: </span> Conceptualization, Writing – Original Draft Preparation </div> <div class=margin-bottom> Leila Maouche-Chr&eacute;tien <br/> <span>Roles: </span> Writing – Review & Editing </div> <div class=margin-bottom> Laurent Frenzel <br/> <span>Roles: </span> Writing – Review & Editing </div> <div class=margin-bottom> Patrice Dubreuil <br/> <span>Roles: </span> Writing – Review & Editing </div> <div class=margin-bottom> Olivier Hermine <br/> <span>Roles: </span> Conceptualization, Writing – Original Draft Preparation, Writing – Review & Editing </div> </p> </div> </div> <div class=contracted-details> <a href="#" class=section-title>Article Versions (1)</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> <div> <a href="https://f1000research.com/articles/8-1961/v1" title="Open version 1 of this article." class="" gahelper=1>version 1</a> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div> Published: 22 Nov 2019, 8:1961 </div> <div class=""><a href="https://doi.org/10.12688/f1000research.19463.1">https://doi.org/10.12688/f1000research.19463.1</a></div> </div> </div> <div class=contracted-details> <a href="#" class=section-title> <span class="f1r-icon icon-100_open_access"></span> Copyright </a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> © 2019 Rossignol J <em>et al</em>. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </div> </div> <div class="padding-top-30 research-layout"> <div class=article-toolbox-wrapper-mobile> <div class=article-tools-icon-mobile data-section=download> <span class="f1r-icon icon-76_download_file white"></span> </div> <div class="article-tools-icon-mobile mobile-metrics article-metrics-wrapper metrics-icon-wrapper" data-section=metrics data-version-id=21341 data-id=19463 data-downloads="" data-views="" data-scholar="10.12688/f1000research.19463.1" data-recommended="" data-f1r-ga-helper="Article Page Metrics (Mobile)"> <span class="f1r-icon icon-89_metrics white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=cite> <span class="f1r-icon icon-82_quote white"></span> </div> <div class="article-tools-icon-mobile " data-section=track> <span class="f1r-icon icon-90_track white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=share> <span class="f1r-icon icon-34_share white"></span> </div> <span class=article-toolbox-stretch></span> </div> <div class=article-toolbox-content-mobile> <div class="toolbox-section download"> <div class=toolbox-section-heading>Download</div> <div class=toolbox-section-content> <a href="https://f1000research.com/articles/8-1961/v1/pdf?article_uuid=f40c1a70-3292-4db5-9d4a-8543dc0a57d2" title="Download PDF" class="no-decoration pdf-download-helper"> <span class="f1r-icon icon-102_download_pdf toolbox-section-icon"></span> </a> <div class=toolbox-section-option-divider>&nbsp;</div> <a id=mobile-download-xml class=no-decoration href="#" title="Download XML"> <span class="f1r-icon icon-103_download_xml toolbox-section-icon"></span> </a> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>Export To</div> <div class=toolbox-section-content> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=WORKSPACE>Sciwheel</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=BIBTEX>Bibtex</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=ENDNOTE>EndNote</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=PROCITE>ProCite</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=REF_MANAGER>Ref. Manager (RIS)</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=SENTE>Sente</button> </div> </div> <div class="toolbox-section metrics"> <div class="toolbox-section-heading no-top-border">metrics</div> <div class="toolbox-section-divider toolbox-section-divider--no-height"></div> <div class=article-metrics-pageinfo> <div class=c-article-metrics-table> <table class=c-article-metrics-table__table> <thead> <tr> <th></th> <th><span class=c-article-metrics-table__heading>Views</span></th> <th><span class=c-article-metrics-table__heading>Downloads</span></th> </tr> </thead> <tbody> <tr> <th class=c-article-metrics-table__row-heading><span class="c-article-metrics-table__platform u-platform--" data-test-id=metrics_platform_name_mob>F1000Research</span></th> <td class="c-article-metrics-table__value js-article-views-count" data-test-id=metrics_platform_views_mob>-</td> <td class="c-article-metrics-table__value js-article-downloads-count" data-test-id=metrics_platform_downloads_mob>-</td> </tr> <tr> <th class=c-article-metrics-table__row-heading> <span class="u-ib u-middle c-article-metrics-table__pmc" data-test-id=metrics_pmc_name_mob>PubMed Central</span> <div class="c-block-tip c-block-tip--centered c-article-metrics-table__tooltip c-block-tip--md-padding c-block-tip--small-arrow u-ib u-middle"> <button type=button class="u-black--medium u-black--high@hover u-ib u-middle c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content>Data from PMC are received and updated monthly.</div> </div> </th> <td class="c-article-metrics-table__value js-pmc-views-count" data-test-id=metrics_pmc_views_mob>-</td> <td class="c-article-metrics-table__value js-pmc-downloads-count" data-test-id=metrics_pmc_downloads_mob>-</td> </tr> </tbody> </table> </div> </div> <span class=metrics-citations-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-heading u-mb--1">Citations</div> <div> <div class=toolbox-section-colsplit> <div class=citations-scopus-logo> <a href="" target=_blank class="is-hidden metrics-citation-icon" title="View full citation details at www.scopus.com"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count scopus"> <a href='' class='scopus-citation-link is-hidden' target=_blank title='View full citation details at www.scopus.com'>0</a> </div> </div> <div class=toolbox-section-colsplit> <div class="citations-pubmed-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon f1000research" title="View full citation details"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count pubmed"> <a href='' class='pubmed-citation-link is-hidden' target=_blank title='View full citation details'>0</a> </div> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <div class="citations-scholar-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon google-scholar f1000research" title="View full citation details" data-scholar="10.12688/f1000research.19463.1"><i class="material-icons scopus-icon">open_in_new</i></a> </div> </div> </div> </span> <span class=metrics-details-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-content altmetric-section"> <div class=altmetrics-image></div> <div class=altmetrics-more-link> <a href="" target=_blank class=f1r-standard-link>SEE MORE DETAILS</a> </div> <div class=altmetric-mobile-column-counts></div> <div class=altmetric-mobile-column-readers></div> <div class=toolbox-section-divider></div> </div> </span> </div> <div class="toolbox-section cite"> <div class="toolbox-section-heading no-top-border">CITE</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>how to cite this article</div> <div id=citation-copy-mobile class="toolbox-section-content text-content heading9 small" data-test-id=mob_copy-citation_text> Rossignol J, Polivka L, Maouche-Chrétien L <em>et al.</em> Recent advances in the understanding and therapeutic management of mastocytosis [version 1; peer review: 4 approved] <i>F1000Research</i> 2019, <b>8</b>(F1000 Faculty Rev):1961 (<a href="https://doi.org/10.12688/f1000research.19463.1" target=_blank>https://doi.org/10.12688/f1000research.19463.1</a>) </div> <div class=toolbox-section-divider></div> <div class="toolbox-section-content text-content heading9 small"> NOTE: <em>it is important to ensure the information in <b>square brackets after the title</b> is included in all citations of this article.</em> </div> <div class=toolbox-section-content> <button class="primary orange extra-padding copy-cite-article-mobile js-clipboard" data-clipboard-target="#citation-copy-mobile" title="Copy the current citation details." data-test-id=mob_copy-citation_button-mob>COPY CITATION DETAILS</button> </div> </div> <div class="toolbox-section track"> <div class="toolbox-section-heading no-top-border">track</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>receive updates on this article</div> <div class="toolbox-section-content padding-left-20 padding-right-20 heading9 small"> Track an article to receive email alerts on any updates to this article. </div> <div class=toolbox-section-content> <a data-article-id=19463 id=mobile-track-article-signin-19463 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/19463?target=/articles/8-1961/v1"> <button class="primary orange extra-padding"> TRACK THIS ARTICLE </button> </a> </div> </div> <div class="toolbox-section share"> <div class="toolbox-section-heading no-top-border">Share</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <a target=_blank class="f1r-shares-icon-square f1r-shares-email" title="Email this article"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-twitter" title="Share on Twitter"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-facebook" title="Share on Facebook"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-linkedin" title="Share on LinkedIn"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-reddit" title="Share on Reddit"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-mendelay" title="Share on Mendeley"></a> <div class="email-article-wrapper email-article-version-container"> <div class=toolbox-section-divider></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form-mobile research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=21341 /> <input name=articleId type=hidden value=19463 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> </div> </div> </div> <a name=article-reports></a> <div id=article-reports class="u-mt--3 reports-comments no-divider"> <div class="current-referee-status current-referee-status--faculty "> <h2 class=main-title id=current-referee-status> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-85_peer_review size30"></span> </span> Open Peer Review <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> <a name=current-referee-status></a> <div class=current-referee-status__content name=add-new-report-comment id=add-new-report-comment> Current Reviewer Status: <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile"> <div class=mobile-ref-status-help> Key to Reviewer Statuses <span class=referee-status-pointer></span> <span class="view-control float-right">VIEW</span> <span class="view-control float-right is-hidden">HIDE</span> <div class=mobile-ref-status-help-content> <div class="cf margin-top"> <span class="f1r-icon icon-86_approved status-green smaller float-left margin-bottom-40 margin-right" title=Approved></span> <span class=title>Approved</span>The paper is scientifically sound in its current form and only minor, if any, improvements are suggested </div> <div class="cf margin-top"> <span class="f1r-icon icon-87_approved_reservations status-green smaller float-left margin-bottom-40 margin-right" title="Approved with Reservations"></span> <span class=title>Approved with reservations</span> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </div> <div class="cf margin-top"> <span class="f1r-icon icon-88_not_approved status-red small float-left margin-bottom-30 margin-right" title="Not Approved"></span> <span class=title>Not approved</span>Fundamental flaws in the paper seriously undermine the findings and conclusions </div> </div> </div> </span> <div class=editorial-note> <h5 class=editorial-note__title>Editorial Note on the Review Process</h5> <p class=editorial-note__text><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home">Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> </div> <div class=approved-referee> <h4 class=approved-referee__title>Reviewers who approved this article</h4> <ol class=approved-referee__list> <li class="approved-referee__list-item "> <span class=approved-referee__co-referee> <strong>Uma Borate</strong>, Division of Hematology & Medical Oncology, Department of Medicine, Oregon Health & Science University, USA </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> <span class=approved-referee__co-referee> <strong>Luke Fletcher</strong>, Division of Hematology & Medical Oncology, Department of Medicine, Oregon Health & Science University, USA </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Stefan W&ouml;hrl</strong>, Floridsdorf Allergy Center (FAZ), Austria </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Yoseph A Mekori</strong>, Sackler Faculty of Medicine, Tel Aviv University, Israel </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Paul LA van Daele</strong>, Department of Internal Medicine, Section of Allergy, Erasmus University Medical Center, The Netherlands </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> </ol> </div> </div> </div> </div> <div class="f1r-article-mobile research-layout"> <div class="mobile-sections-divider before-comments"></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 22 Nov 2019</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/8-1961/v1&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/8-1961/v1&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> </div> </div> <div id=article_main-column class="p-article__sidebar o-layout__item u-1/3 not-expanded js-article-sidebar"> <div class="o-tab p-article__column-toggle-container"> <button class="c-tab c-tab--left js-column-toggle p-article__column-toggle not-expanded " type=button data-target-main=article_main-column data-target-secondary=article_secondary-column><i class="c-tab__icon material-icons u-hide@expanded">keyboard_arrow_left</i><i class="c-tab__icon material-icons u-show@expanded">keyboard_arrow_right</i></button> </div> <div class=p-article__sidebar-content> <div class="p-article__sidebar-scroller js-article-sidebar-scroller"> <section class="p-article__sidebar-view js-article-sidebar-view js-article-sidebar-main u-pt u-pb--8" data-view=peer-review> <div class="o-layout o-layout--flush"> <div class="o-layout__item u-pl"> <h3 class="u-mt--0 u-mb--2 t-h3 u-weight--md u-pl" data-test-id=article_sidebar_heading>Open Peer Review</h3> </div> <div class=o-layout__item> <section class=""> <div class="p-article__sidebar-highlight u-mb--2 u-pr--1"> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md u-mr--1/2">Reviewer Status</h4> <div class="c-referee-status__icons u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=60136-56547></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=60138-56549></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=60137-56550></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=60132-56548></i> </div> </div> <div class="o-actions__secondary _mdl-layout"> <div class="c-block-tip p-article__sidebar-tooltip c-block-tip--below c-block-tip--small-arrow c-block-tip--sm-padding"> <button type=button class="c-button c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content> <p class="t-body u-mt--0 u-mb--0"><em class=u-weight--md>Alongside their report, reviewers assign a status to the article:</em></p> <dl class=c-definitions> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved</span></dt> <dd class="c-definitions__description t-caption">The paper is scientifically sound in its current form and only minor, if any, improvements are suggested</dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--reservations" title="Approved with Reservations" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved with reservations</span></dt> <dd class="c-definitions__description t-caption"> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--not-approved " title="Not Approved" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Not approved</span></dt> <dd class="c-definitions__description t-caption">Fundamental flaws in the paper seriously undermine the findings and conclusions</dd> </dl> </div> </div> </div> </div> </div> <div class="o-layout__item u-mb--1"><h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md">Reviewer Reports</h4></div> <table class="c-report-timeline u-mb--2"> <thead class=c-report-timeline__headings> <tr> <th></th> <th class="u-pb--1/2" colspan=4><em class="t-body u-weight--rg">Invited Reviewers</em></th> </tr> <tr class=c-report-timeline__headings-row> <th></th> <th class="c-report-timeline__headings-version p-article__color--dark">1</th> <th class="c-report-timeline__headings-version p-article__color--dark">2</th> <th class="c-report-timeline__headings-version p-article__color--dark">3</th> <th class="c-report-timeline__headings-version p-article__color--dark">4</th> </tr> </thead> <tbody> <tr class="c-report-timeline__row c-report-timeline__row--selected "> <th class=c-report-timeline__version> <a data-test-id=sidebar_timeline_v1_version href="https://f1000research.com/articles/8-1961/v1">Version 1</a><br/> <span class=p-article__color--dark> <span data-test-id=sidebar_timeline_v1_date class=c-report-timeline__date>22 Nov 19</span> </span> </th> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> </tr> </tbody> </table> <div class=o-layout__item> <hr class="c-hr c-hr--low u-mb--2"> </div> </section> </div> <div class=o-layout__item> <div class="u-pl u-pr"> <p class="t-body u-mt--0 u-mb--2"><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home" target=_blank class=in-text-link>Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> <ol class="p-article__faculty-referee-list t-caption"> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Uma Borate</strong>, Division of Hematology & Medical Oncology, Department of Medicine, Oregon Health & Science University, USA </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> <p class=" u-mt--2 u-mb--1/2"><strong>Luke Fletcher</strong>, Division of Hematology & Medical Oncology, Department of Medicine, Oregon Health & Science University, USA </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Stefan W&ouml;hrl</strong>, Floridsdorf Allergy Center (FAZ), Austria </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Yoseph A Mekori</strong>, Sackler Faculty of Medicine, Tel Aviv University, Israel </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Paul LA van Daele</strong>, Department of Internal Medicine, Section of Allergy, Erasmus University Medical Center, The Netherlands </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> </ol> </div> </div> <section class="o-layout__item u-pl"> <div class=u-pl> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--2">Comments on this article</h4> <div class=u-mb--4> <p class="u-mt--0 u-mb--1 t-h4"><a class=p-article__color--light href="#article-comments">All Comments</a><span class=" u-ib u-ml--1/2 p-article__color--light">(0)</span></p> <a class=t-h4 href="/login?originalPath=/articles/8-1961/v1&scrollTo=add-new-comment" data-test-id=add-comment>Add a comment</a> </div> <hr class="c-hr c-hr--low c-hr--md u-mb--4"> <div class="research-layout f1r-article-desk"> <div class="heading6 c-ribbon-wrapper c-ribbon-wrapper--etoc f1000research "> <div class=c-ribbon-wrapper__body>Sign up for content alerts</div> </div> </div> <div class="research-layout sidebar-sign-up-form f1r-article-desk u-mb--4 "> <form class=js-email-alert-signup action="#" method=POST data-email=tocAlertWeekly> <input type=hidden name=isUserLoggedIn class=js-email-alert-signup-logged-in value=N /> <input type=hidden name=userId class=js-email-alert-signup-user-id value=""/> <input type=hidden name=frequency class=js-email-alert-signup-frequency value=WEEKLY /> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <input type=email name=emailAddress class="form-input-field js-email-alert-signup-address u-1/1 u-bb" required=required placeholder=Email /> </div> <div class=o-actions__secondary> <div class="_mdl-layout u-ml--1/2"> <button class="mdl-button mdl-js-button mdl-button--colored mdl-button--small mdl-button--filled js-email-alert-signup-submit">Sign Up</button> </div> </div> </div> </form> <div id=sidebar-sign-up-message class="section-text js-email-alert-signup-msg is-hidden">You are now signed up to receive this alert</div> </div> <section class=js-terms-container> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--1">Browse by related subjects</h4> <div class="article-subcontainer article-subcontainer--sidebar"> <ul class=js-terms-list></ul> </div> </section> </div> </section> </div> </section> </div> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/read-more.js"></script> <script src="/js/article/article-router.js"></script> <script src="/js/article/article-sidebar.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/article/article-column-toggle.js"></script> </div> </div> </div> </main> <input type=hidden id=_articleVersionUrl value="https://f1000research.com/articles/8-1961/v1/"> <div class=research-help id=about-referee-status> <div class="research-layout research-help-content about-referee-status"> <span class="close-research-help dark-cross" title=Close></span> Alongside their report, reviewers assign a status to the article: <div class="cf research-help-row"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> <span class=research-help-text>Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested</span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-87_approved_reservations status-green smaller" title="Approved with Reservations"></span> <span class=research-help-text>Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-88_not_approved status-red small" title="Not Approved"></span> <span class=research-help-text>Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions</span> </div> </div> </div> <div id=datasets-info class=is-hidden> </div> <div class=article-interactive-content-container style="display: none;"> <a name=f-template class=n-a></a> <div class="interactive-content-wrapper padding-20"> <img src="" class=interactive-content-image title="Open the interactive image display"> <div class=interactive-content-title></div> <div class=interactive-content-text></div> <div class="f1r-article-desk interactive-content-ribbon" data-interactive-content-type=R-Script> <div class=interactive-content-label>Adjust parameters to alter display</div> <div class=interactive-content-button></div> </div> <div class="f1r-article-mobile mobile-interactive-note"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div id=article-interactive-omero-container class=article-interactive-omero-container style="display: none;"> <div class=interactive-content-wrapper> <div class="interactive-omero-button omero-content" title="Open the interactive content window." data-interactive-content-type=Omero></div> <div class=has-interactive-content-image> <span class=box-arrow></span> <span class=box-middle>Includes Interactive Elements</span> <span class=box-end></span> </div> <div class="fig panel clearfix" style="margin: 0; padding-bottom: 20px;"> <a name=templatelink class=n-a></a> <a target=_blank href="" class=link-for-omero-image> <img src="" class=interactive-omero-image title="Open the image display window."> </a> <div class=caption> <div class=interactive-content-title></div> <div class=interactive-content-text></div> </div> <div class="is-hidden omero-image-list"></div> </div> <div class="f1r-article-mobile mobile-interactive-note omero"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div class="add-comment-container shadow-box is-hidden" id=save-comment-container> <span id=save-comment-text class=intro-text>Edit comment</span> <textarea id=new-comment name=new-comment class="global-textarea comment margin-bottom margin-top"></textarea> <p><strong>Competing Interests</strong></p> <textarea id=new-competing-interests name=competing-interests class="global-textarea competing-interests margin-bottom check-xss"></textarea> <div class=clearfix></div> <button id=cancelComment type=button class="general-white-orange-button float-right no-background-button margin-left"> Cancel </button> <button id=save-comment-button commentId="" type=button class="general-white-orange-button float-right"> Save </button> <div class=clearfix></div> <div class="green-message margin-top is-hidden comment-is-saved">The comment has been saved.</div> <div class="red-message margin-top is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class="red-message margin-top is-hidden comment-enter-text ucf">Your must enter a comment.</div> <div class="red-message margin-top is-hidden comment-references-error references">References error.</div> </div> <div class="modal-window-wrapper is-hidden"> <div id=conflicts-interests class="modal-window padding-20"> <div class=modal-window__content> <h2 class=h2-title>Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div class="f1r-article-mobile research-layout"> <span class=modal-window-close-button></span> </div> </div> </div> <div class="o-modal c-email-alert-popup js-email-alert-popup is-hidden"> <div class="o-modal__body js-modal-body c-email-alert-popup__inner"> <h3 class=c-email-alert-popup__title>Stay Updated</h3> <p class=c-email-alert-popup__sub>Sign up for content alerts and receive a weekly or monthly email with all newly published articles</p> <p><a href="/register?originalPath=" class="c-email-alert-popup__lnk c-email-alert-popup__button js-email-alert-popup-action">Register with F1000Research</a></p> <p>Already registered? <a href="/login?originalPath=" class="c-email-alert-popup__lnk js-email-alert-popup-action">Sign in</a></p> <p class=c-email-alert-popup__footer><a class="c-email-alert-popup__lnk js-email-alert-popup-cancel" href="#">Not now, thanks</a></p> </div> </div> <div id=addCommentModal role=dialog aria-labelledby=addCommentModal_title aria-describedby=addCommentModal_description> <div class="c-modal js-modal is-closed p-article__add-comment-modal c-modal--xlarge js-article-comment-modal c-modal--scroll "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-bg--2 c-modal--scroll-always "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <div id=addCommentModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div class="js-add-comment-container t-caption u-black--high"> <div class=u-weight--bd>PLEASE NOTE</div> <div class=u-mt--1> <span class="red u-weight--bd">If you are an AUTHOR of this article,</span> please check that you signed in with the account associated with this article otherwise we cannot automatically identify your role as an author and your comment will be labelled as a &ldquo;User Comment&rdquo;. </div> <div class=u-mt--1> <span class="red u-weight--bd">If you are a REVIEWER of this article,</span> please check that you have signed in with the account associated with this article and then go to your <a href="/my/referee">account</a> to submit your report, please do not post your review here. </div> <div class="u-mt--1 u-mb--1"> If you do not have access to your original account, please <a href="mailto:research@f1000.com">contact us</a>. </div> <p class=no-top-margin>All commenters must hold a formal affiliation as per our <a href="/about/policies#commentspolicy" target=_blank>Policies</a>. The information that you give us will be displayed next to your comment.</p> <p>User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the <a href="/about/legal/usercommenttermsandconditions" target=_blank>User Comment Terms and Conditions</a>. Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available.</p> <div class="comments-note margin-bottom" id=accept-user-comments> <input class=js-add-comment-accept-terms type=checkbox id=acceptedTermsAndConditions name=acceptedTermsAndConditions> I accept the <a href="/about/legal/usercommenttermsandconditions" target=_blank> User Comment Terms and Conditions</a> <span class=required>&nbsp;</span> </div> <div class="default-error margin-top is-hidden comment-accept-conditions utac">Please confirm that you accept the User Comment Terms and Conditions.</div> <div class="research-layout registration-form u-mb--2"> <div class="u-mb--1 u-mt--2"> <strong>Affiliation</strong> </div> <div class=form-field> <input type=text name=institution class="form-input-field check-xss js-add-comment-institution" placeholder="Organization *" autocomplete=off /> <div class="default-error margin-top is-hidden comment-enter-institution institution">Please enter your organisation.</div> </div> <div class=form-field> <input type=text name=place class="form-input-field check-xss js-add-comment-place" placeholder=Place> </div> <div class=form-field> <div class="form-input-wrapper hundred-percent-wide"> <div class="new-select-standard-wrapper half-width inline-display heading10"> <select name=countryId id=country class="form-select-menu smaller js-add-comment-country"> <option value=-1>Country*</option> <option value=840>USA</option> <option value=826>UK</option> <option value=124>Canada</option> <option value=156>China</option> <option value=250>France</option> <option value=276>Germany</option> <optgroup label=-----------------------------------------------></optgroup> <option value=4>Afghanistan</option> <option value=248>Aland Islands</option> <option value=8>Albania</option> <option value=12>Algeria</option> <option value=16>American Samoa</option> <option value=20>Andorra</option> <option value=24>Angola</option> <option value=660>Anguilla</option> <option value=10>Antarctica</option> <option value=28>Antigua and Barbuda</option> <option value=32>Argentina</option> <option value=51>Armenia</option> <option value=533>Aruba</option> <option value=36>Australia</option> <option value=40>Austria</option> <option value=31>Azerbaijan</option> <option value=44>Bahamas</option> <option value=48>Bahrain</option> <option value=50>Bangladesh</option> <option value=52>Barbados</option> <option value=112>Belarus</option> <option value=56>Belgium</option> <option value=84>Belize</option> <option value=204>Benin</option> <option value=60>Bermuda</option> <option value=64>Bhutan</option> <option value=68>Bolivia</option> <option value=70>Bosnia and Herzegovina</option> <option value=72>Botswana</option> <option value=74>Bouvet Island</option> <option value=76>Brazil</option> <option value=86>British Indian Ocean Territory</option> <option value=92>British Virgin Islands</option> <option value=96>Brunei</option> <option value=100>Bulgaria</option> <option value=854>Burkina Faso</option> <option value=108>Burundi</option> <option value=116>Cambodia</option> <option value=120>Cameroon</option> <option value=124>Canada</option> <option value=132>Cape Verde</option> <option value=136>Cayman Islands</option> <option value=140>Central African Republic</option> <option value=148>Chad</option> <option value=152>Chile</option> <option value=156>China</option> <option value=162>Christmas Island</option> <option value=166>Cocos (Keeling) Islands</option> <option value=170>Colombia</option> <option value=174>Comoros</option> <option value=178>Congo</option> <option value=184>Cook Islands</option> <option value=188>Costa Rica</option> <option value=384>Cote d'Ivoire</option> <option value=191>Croatia</option> <option value=192>Cuba</option> <option value=196>Cyprus</option> <option value=203>Czech Republic</option> <option value=180>Democratic Republic of the Congo</option> <option value=208>Denmark</option> <option value=262>Djibouti</option> <option value=212>Dominica</option> <option value=214>Dominican Republic</option> <option value=218>Ecuador</option> <option value=818>Egypt</option> <option value=222>El Salvador</option> <option value=226>Equatorial Guinea</option> <option value=232>Eritrea</option> <option value=233>Estonia</option> <option value=231>Ethiopia</option> <option value=238>Falkland Islands</option> <option value=234>Faroe Islands</option> <option value=583>Federated States of Micronesia</option> <option value=242>Fiji</option> <option value=246>Finland</option> <option value=250>France</option> <option value=254>French Guiana</option> <option value=258>French Polynesia</option> <option value=260>French Southern Territories</option> <option value=266>Gabon</option> <option value=268>Georgia</option> <option value=276>Germany</option> <option value=288>Ghana</option> <option value=292>Gibraltar</option> <option value=300>Greece</option> <option value=304>Greenland</option> <option value=308>Grenada</option> <option value=312>Guadeloupe</option> <option value=316>Guam</option> <option value=320>Guatemala</option> <option value=831>Guernsey</option> <option value=324>Guinea</option> <option value=624>Guinea-Bissau</option> <option value=328>Guyana</option> <option value=332>Haiti</option> <option value=334>Heard Island and Mcdonald Islands</option> <option value=336>Holy See (Vatican City State)</option> <option value=340>Honduras</option> <option value=344>Hong Kong</option> <option value=348>Hungary</option> <option value=352>Iceland</option> <option value=356>India</option> <option value=360>Indonesia</option> <option value=364>Iran</option> <option value=368>Iraq</option> <option value=372>Ireland</option> <option value=376>Israel</option> <option value=380>Italy</option> <option value=388>Jamaica</option> <option value=392>Japan</option> <option value=832>Jersey</option> <option value=400>Jordan</option> <option value=398>Kazakhstan</option> <option value=404>Kenya</option> <option value=296>Kiribati</option> <option value=901>Kosovo (Serbia and Montenegro)</option> <option value=414>Kuwait</option> <option value=417>Kyrgyzstan</option> <option value=418>Lao People's Democratic Republic</option> <option value=428>Latvia</option> <option value=422>Lebanon</option> <option value=426>Lesotho</option> <option value=430>Liberia</option> <option value=434>Libya</option> <option value=438>Liechtenstein</option> <option value=440>Lithuania</option> <option value=442>Luxembourg</option> <option value=446>Macao</option> <option value=807>Macedonia</option> <option value=450>Madagascar</option> <option value=454>Malawi</option> <option value=458>Malaysia</option> <option value=462>Maldives</option> <option value=466>Mali</option> <option value=470>Malta</option> <option value=584>Marshall Islands</option> <option value=474>Martinique</option> <option value=478>Mauritania</option> <option value=480>Mauritius</option> <option value=175>Mayotte</option> <option value=484>Mexico</option> <option value=581>Minor Outlying Islands of the United States</option> <option value=498>Moldova</option> <option value=492>Monaco</option> <option value=496>Mongolia</option> <option value=499>Montenegro</option> <option value=500>Montserrat</option> <option value=504>Morocco</option> <option value=508>Mozambique</option> <option value=104>Myanmar</option> <option value=516>Namibia</option> <option value=520>Nauru</option> <option value=524>Nepal</option> <option value=530>Netherlands Antilles</option> <option value=540>New Caledonia</option> <option value=554>New Zealand</option> <option value=558>Nicaragua</option> <option value=562>Niger</option> <option value=566>Nigeria</option> <option value=570>Niue</option> <option value=574>Norfolk Island</option> <option value=580>Northern Mariana Islands</option> <option value=408>North Korea</option> <option value=578>Norway</option> <option value=512>Oman</option> <option value=586>Pakistan</option> <option value=585>Palau</option> <option value=275>Palestinian Territory</option> <option value=591>Panama</option> <option value=598>Papua New Guinea</option> <option value=600>Paraguay</option> <option value=604>Peru</option> <option value=608>Philippines</option> <option value=612>Pitcairn</option> <option value=616>Poland</option> <option value=620>Portugal</option> <option value=630>Puerto Rico</option> <option value=634>Qatar</option> <option value=638>Reunion</option> <option value=642>Romania</option> <option value=643>Russian Federation</option> <option value=646>Rwanda</option> <option value=654>Saint Helena</option> <option value=659>Saint Kitts and Nevis</option> <option value=662>Saint Lucia</option> <option value=666>Saint Pierre and Miquelon</option> <option value=670>Saint Vincent and the Grenadines</option> <option value=882>Samoa</option> <option value=674>San Marino</option> <option value=678>Sao Tome and Principe</option> <option value=682>Saudi Arabia</option> <option value=686>Senegal</option> <option value=688>Serbia</option> <option value=690>Seychelles</option> <option value=694>Sierra Leone</option> <option value=702>Singapore</option> <option value=703>Slovakia</option> <option value=705>Slovenia</option> <option value=90>Solomon Islands</option> <option value=706>Somalia</option> <option value=710>South Africa</option> <option value=239>South Georgia and the South Sandwich Is</option> <option value=410>South Korea</option> <option value=724>Spain</option> <option value=144>Sri Lanka</option> <option value=736>Sudan</option> <option value=740>Suriname</option> <option value=744>Svalbard and Jan Mayen</option> <option value=748>Swaziland</option> <option value=752>Sweden</option> <option value=756>Switzerland</option> <option value=760>Syria</option> <option value=158>Taiwan</option> <option value=762>Tajikistan</option> <option value=834>Tanzania</option> <option value=764>Thailand</option> <option value=270>The Gambia</option> <option value=528>The Netherlands</option> <option value=626>Timor-Leste</option> <option value=768>Togo</option> <option value=772>Tokelau</option> <option value=776>Tonga</option> <option value=780>Trinidad and Tobago</option> <option value=788>Tunisia</option> <option value=792>Turkey</option> <option value=795>Turkmenistan</option> <option value=796>Turks and Caicos Islands</option> <option value=798>Tuvalu</option> <option value=800>Uganda</option> <option value=826>UK</option> <option value=804>Ukraine</option> <option value=784>United Arab Emirates</option> <option value=850>United States Virgin Islands</option> <option value=858>Uruguay</option> <option value=840>USA</option> <option value=860>Uzbekistan</option> <option value=548>Vanuatu</option> <option value=862>Venezuela</option> <option value=704>Vietnam</option> <option value=876>Wallis and Futuna</option> <option value=905>West Bank and Gaza Strip</option> <option value=732>Western Sahara</option> <option value=887>Yemen</option> <option value=894>Zambia</option> <option value=716>Zimbabwe</option> </select> </div> </div> <div class="default-error margin-top is-hidden comment-enter-country country">Please select your country.</div> </div> </div> <textarea data-test-id=article_add-comment_comment name=new-comment class="js-add-comment-comment comment margin-bottom margin-top"></textarea> <div class="default-error margin-top comment-enter-text comment-error is-hidden ">You must enter a comment.</div> <label class="comments-note u-mt--2 u-mb--2" for=competingInterests_1> <div class="u-mb--1 u-mt--2"><strong data-test-id=article_report-add-comment_competing-interests-title>Competing Interests</strong></div> <p class="u-mb--2 u-mt--0" data-test-id=article_report-add-comment_competing-interests-description>Please disclose any <a href="#article-competing-intersts-policy" class=js-modal-competing-intersts-toggle>competing interests</a> that might be construed to influence your judgment of the article's or peer review report's validity or importance.</p> </label> <div id=article-competing-intersts-policy class=js-article-competing-interests-policy style="display: none;"> <h2 class="h2-title u-mt--0 u-pt--0">Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div id=competingInterests_1 class="c-inline-editor js-inline-editor js-form_input u-bb--all u-mb--2 js-comment-competing-interests" data-name=competing-interests data-rows=3> <textarea id=competingInterests_1_input name=competing-interests placeholder="&nbsp;" required=false class="u-hide-visually js-inline-editor_input" tabindex=-1></textarea> <div class="c-inline-editor__editor js-inline-editor_editor o-box c-box o-box--tiny u-bg--11" data-target=competingInterests_1_input role=textbox required=false data-placeholder="&nbsp;" contenteditable=true></div> <span class="c-inline-editor__error js-inline-editor-message">Please state your competing interests</span> </div> <div data-test-id=article_add-comment_saved class="green-message comments is-hidden comment-is-saved">The comment has been saved.</div> <div data-test-id=article_add-comment_error class="default-error comments is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class=clearfix></div> <div class=js-hook></div> </div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" data-test-id=article_add-comment_cancel class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" data-test-id=article_add-comment_post class="c-button c-button--full js-modal__confirm c-button--primary">Post</a> </div> </aside> </div> </div> <style>
                .at-icon-wrapper {
        background-size: 100% !important;
    }
</style> <script src="/js/namespace.js"></script> <script src="/js/constants.js"></script> <script src="/js/utilities.js"></script> <script src="/js/article/alert-signup.js"></script> <script type='text/javascript'>
    var lTitle = "Recent advances in the understanding and...".replace("'", '');
    var linkedInUrl = "http://www.linkedin.com/shareArticle?url=https://f1000research.com/articles/8-1961/v1" + "&title=" + encodeURIComponent(lTitle) + "&summary=" + encodeURIComponent('Read the article by ');

    var deliciousUrl = "https://del.icio.us/post?url=https://f1000research.com/articles/8-1961/v1&title=" + encodeURIComponent(lTitle);

    var redditUrl = "http://reddit.com/submit?url=https://f1000research.com/articles/8-1961/v1" + "&title=" + encodeURIComponent(lTitle);

            linkedInUrl += encodeURIComponent('Rossignol J et al.');
    
    var offsetTop = /chrome/i.test( navigator.userAgent ) ? 4 : -10; 
    var addthis_config = {
            ui_offset_top: offsetTop,
                                    services_compact : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_expanded : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_custom : [
                {
                    name: "LinkedIn",
                    url:  linkedInUrl,
                    icon:"/img/icon/at_linkedin.svg"
                },
                {
                    name: "Mendeley",
                    url:  "http://www.mendeley.com/import/?url=https://f1000research.com/articles/8-1961/v1/mendeley",
                    icon:"/img/icon/at_mendeley.svg"
                },
                {
                    name: "Reddit",
                    url:  redditUrl,
                    icon:"/img/icon/at_reddit.svg"
                },
            ]
        };


    var addthis_share = {
            url: "https://f1000research.com/articles/8-1961",
            templates : {
                twitter : "Recent advances in the understanding and therapeutic management.... Rossignol J et al., published by " + 
               "@F1000Research"
       + ", https://f1000research.com/articles/8-1961/v1"
            }
        };

    if (typeof(addthis) != "undefined"){
        addthis.addEventListener('addthis.ready', checkCount);
        addthis.addEventListener('addthis.menu.share', checkCount);
    }

        $(".f1r-shares-twitter").attr("href", "https://twitter.com/intent/tweet?text=" + addthis_share.templates.twitter);
    $(".f1r-shares-facebook").attr("href", "https://www.facebook.com/sharer/sharer.php?u=" + addthis_share.url);
    $(".f1r-shares-linkedin").attr("href", addthis_config.services_custom[0].url);
    $(".f1r-shares-reddit").attr("href", addthis_config.services_custom[2].url);
    $(".f1r-shares-mendelay").attr("href", addthis_config.services_custom[1].url);

    function checkCount(){
        setTimeout(function(){
            $(".addthis_button_expanded").each(function(){
                var count = $(this).text();
                if (count !== "" && count != "0")
                    $(this).removeClass("is-hidden");
                else
                    $(this).addClass("is-hidden");
            });
        }, 1000);
    }
</script> <div id=citeReportModal role=dialog aria-labelledby=citeReportModal_title aria-describedby=citeReportModal_description> <div class="c-modal js-modal is-closed c-modal--large js-cite-report-modal "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-black--high "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <h1 id=citeReportModal_title class="c-modal__title t-h3 u-mt--0 u-mb--2 u-weight--md">How to cite this report</h1> <div id=citeReportModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div id="" class=js-report-citation-container>{{reportCitation}}</div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" title="Copy the current citation details to the clipboard." data-clipboard-target="#referee-report-citation" data-test-id=report_copy-citation_button class="c-button c-button--full js-modal__confirm c-button--primary js-clipboard c-mini-tooltip--above">Copy Citation Details</a> </div> </aside> </div> </div> <script src="/js/referee/new/referee_validators.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/referee/new/referee_checkbox-input.js"></script> <script src="/js/referee/new/referee_inline-editor.js"></script> <script type="text/javascript">
    $(function(){
        var gaCat = "F1000Research";
        if (gaCat === "") {
            gaCat = $("body").hasClass("wellcome-brand") ? "Wellcome Open Research" : "F1000Research";
        }
        GAHelper.track({category: gaCat, action: "Article Page: Recent advances in the understanding and therapeutic management of mastocytosis", label: "pageviews"});
        GAHelper.track({category: gaCat, action: "Article Type: Review", label: "Article Page"});
        $(".f1r-article-desk .collection-image").each(function (idx, el) {
            var whatChannel = $(el).find("a").attr("href"),
                channelName = $.trim($(el).parent().find(".collection-detail a").text()),
                gaRef = "(ID: " + whatChannel.replace("/collections/", "") + ") " + channelName;
            GAHelper.track({category: 'ChannelStats', action: "Article Page: Recent advances in the understanding and therapeutic management of mastocytosis", label: gaRef});
        });
    });
</script> <script>
    $(function(){R.ui.buttonDropdowns('.dropdown-for-downloads');});
    $(function(){R.ui.toolbarDropdowns('.toolbar-dropdown-for-downloads');});
</script> <script src="/js/article/track_article.js" type="text/javascript"></script> <script type="text/javascript">
    $.get("/articles/acj/19463/21341")
</script> <script type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js"></script> <script type="text/javascript" src="/js/app/messenger.js"></script> <script type="text/javascript" src="/js/article/article_mobiles.js"></script> <script src="/js/vendor/clipboard.min.js"></script> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/clipboard.js"></script> <script src="/js/article/thesaurus-terms-display.js"></script> <script>
    new F1000.Clipboard();
    new F1000.ThesaurusTermsDisplay("faculty-reviews", "article", "21341");
</script> <script>
    $(document).ready(function() {
        $( "#frame1" ).on('load', function() {
            var mydiv = $(this).contents().find("div");
            var h     = mydiv.height();
            console.log(h)
        });

        
        var tooltipLivingFigure = jQuery(".interactive-living-figure-label .icon-more-info"),
            titleLivingFigure = tooltipLivingFigure.attr("title");
        tooltipLivingFigure.simpletip({
            fixed: true,
            position: ["-115", "30"],
            baseClass: 'small-tooltip',
            content:titleLivingFigure + "<div class='tooltip-arrow'></div>"
        });
        tooltipLivingFigure.removeAttr("title");

        $("body").on("click", ".cite-living-figure", function(e) {
            e.preventDefault();
            var ref = $(this).attr("data-ref");
            $(this).closest(".living-figure-list-container").find("#" + ref).fadeIn(200);
        });
        $("body").on("click", ".close-cite-living-figure", function(e) {
            e.preventDefault();
            $(this).closest(".popup-window-wrapper").fadeOut(200);
        });

                $(document).on("mouseup", function(e) {
            var metricsContainer = $(".article-metrics-popover-wrapper");
            if (!metricsContainer.is(e.target) && metricsContainer.has(e.target).length === 0) {
                $(".article-metrics-close-button").click();
            }
        });

        var articleId = $('#articleId').val();

        if($("#main-article-count-box").attachArticleMetrics) {
            $("#main-article-count-box").attachArticleMetrics(articleId, {
                articleMetricsView: true
            });
        }
    });

    var figshareWidget = $(".new_figshare_widget");
    if (figshareWidget.length > 0) {
        window.figshare.load("f1000", function(Widget) {
            // Select a tag/tags defined in your page. In this tag we will place the widget.
            _.map(figshareWidget, function(el){
                var widget = new Widget({
                    articleId: $(el).attr("figshare_articleId")
                    //height:300 // this is the height of the viewer part. [Default: 550]
                });
                widget.initialize(); // initialize the widget
                widget.mount(el); // mount it in a tag that's on your page
                // this will save the widget on the global scope for later use from
                // your JS scripts. This line is optional.
                //window.widget = widget;
            });
        });
    }
</script>

<script>
    $(document).ready(function () {

        
        var reportIds = {
                           "56547": 1,
                           "56548": 1,
                           "56549": 1,
                           "56550": 2,
                    };

        $(".referee-response-container,.js-referee-report").each(function(index, el) {
            var reportId = $(el).attr("data-reportid"),
                reportCount = reportIds[reportId] || 0;
            $(el).find(".comments-count-container,.js-referee-report-views").html(reportCount);
        });

        var uuidInput = $("#article_uuid"),
            oldUUId = uuidInput.val(),
            newUUId = "f4ce1433-d9ad-4288-8014-f1c07234deb9";
        uuidInput.val(newUUId);

        $("a[href*='article_uuid=']").each(function(index, el) {
            var newHref = $(el).attr("href").replace(oldUUId, newUUId);
            $(el).attr("href", newHref);
        });

    });
</script>              </div>
        </div>

        
            
            <div class="o-page__footer sticky-email-wrapper">
                
                

                


<footer class="c-footer t-inverted">

    <div class="o-wrapper">
        <div class="o-layout">


                        
            <div class="o-layout__item u-mb--3">
                <div class="c-branding c-branding--research">
                    <img src="/img/research/F1000Research_white.svg" alt="F1000Research">
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <p class="t-h3 u-mt--0 u-mb--0">An innovative open access publishing platform offering rapid publication and open peer review, whilst supporting data deposition and sharing.</p>

            </div>


                        
            <div class="o-layout__item u-2/3@md">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <div class="o-layout">
                    <nav class="c-footer__nav">

                            <div class="o-layout__item u-3/5@sm u-mb--3">


                                <div class="o-columns o-columns--2">

                                                                            <a href="/browse/articles" class="t-body c-footer__nav-item "      >Browse</a>
                                                                            <a href="/gateways" class="t-body c-footer__nav-item "      >Gateways</a>
                                                                            <a href="/collections" class="t-body c-footer__nav-item "      >Collections</a>
                                                                            <a href="/about" class="t-body c-footer__nav-item "      >How it Works</a>
                                                                            <a href="https://blog.f1000.com/blogs/f1000research/" class="t-body c-footer__nav-item "      >Blog</a>
                                                                            <a href="/contact" class="t-body c-footer__nav-item "      >Contact</a>
                                                                            <a href="/developers" class="t-body c-footer__nav-item u-hide u-show@navbar"      >For Developers</a>
                                                                            <a href="/published/rss" class="t-body c-footer__nav-item "   title="RSS feed of published articles"     >RSS</a>
                                    
                                </div>

                            </div>

                            <div class="o-layout__item u-2/5@sm u-center u-right@sm u-mb--3">

                                <div class="u-hide u-show@lg">
                                    <div class="_mdl-layout">
                                        <a class="mdl-button mdl-js-button mdl-button--inverted mdl-button--no-shadow mdl-js-ripple-effect mdl-button--outline" href="/for-authors/publish-your-research"   data-test-id="footer_submit_research"  >Submit Your Research</a>
                                    </div>
                                </div>

                            </div>

                    </nav>
                </div>

            </div>

            <div class="o-layout__item u-mb--2">
                <div class="c-footer__share">
                        <div class="c-footer__share">
        <span class="c-footer__share-icon" title="Open Access">
            <span class="f1r-icon icon-100_open_access license-icon"></span>
        </span>

        <a class="c-footer__share-icon" href="//creativecommons.org/licenses" target="_blank" title="Creative Commons License CC-BY">
            <span class="f1r-icon icon-116_cc license-icon license-icon-cc"></span>
            <span class="f1r-icon icon-117_ccby license-icon license-icon-cc"></span>
        </a>

        <a class="c-footer__share-icon" href="//creativecommons.org/about/cc0" target="_blank" title="Creative Commons License CC0">
            <span class="f1r-icon icon-118_cco license-icon"></span>
        </a>

    </div>
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="c-footer__social u-mt--0 u-mb--0 u-white--low-med">Follow us
                    <a href="https://www.facebook.com/F1000" target="_blank" class="c-footer__social-icon f1r-icon icon-55_footer_facebook"></a>
                    <a href="https://twitter.com/#!/F1000Research" target="_blank" class="c-footer__social-icon f1r-icon icon-56_footer_twitter"></a>
                    <a href="http://www.youtube.com/user/F1000research" target="_blank" class="c-footer__social-icon f1r-icon icon-57_footer_youtube"></a></p>

            </div>


                        
            <div class="o-layout__item u-2/3@md u-right@md">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="t-caption u-white--low-med">&copy; 2012-2020 F1000 Research Ltd. ISSN 2046-1402 | <a href="/about/legal" class="copyrightLegal">Legal</a> | Partner of <a target="_blank" href="http://www.who.int/hinari/en/">HINARI</a>  &bull; <a target="_blank" href="http://crossref.org/">CrossRef</a> &bull; <a target="_blank" href="http://about.orcid.org/">ORCID</a> &bull; <a target="_blank" href="http://www.fairsharing.org">FAIRSharing</a></p>

            </div>
        </div>
    </div>

</footer>            </div>
        
    </div>

            <div class="js-cookie-spacer"></div>
        <div class="cookie-warning">
            <div class="instruction">The F1000Research website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. <a class="js-scroll-to" href="/about/legal/privacypolicy#use-of-cookies" data-scroll-target="#use-of-cookies">Find out more &raquo;</a></div>
            <div class="close-button"></div>
        </div>
    
    <script>
                    R.templateTests.simpleTemplate = R.template('<p class="$variable.one">$text</p><p class="${variable.two}">$text</p><p class="$!variable.three">$text</p><p class="$!{variable.four}">$text</p><p class="${selector}.five">$text</p>');
            R.templateTests.runTests();
        
        var F1000platform = new F1000.Platform({
            name: "f1000research",
            displayName: "F1000Research",
            hostName: "f1000research.com",
            id: "1",
            editorialEmail: "research@f1000.com",
            infoEmail: "info@f1000.com",
            usePmcStats: true
        });

                    $(function(){R.ui.dropdowns('.dropdown-for-authors, .dropdown-for-about, .dropdown-for-myresearch');});
            // $(function(){R.ui.dropdowns('.dropdown-for-referees');});

            $(document).ready(function () {
                if ($(".cookie-warning").is(":visible")) {
                    $(".sticky").css("margin-bottom", "35px");
                    $(".devices").addClass("devices-and-cookie-warning");
                }
                $(".cookie-warning .close-button").click(function (e) {
                    $(".devices").removeClass("devices-and-cookie-warning");
                    $(".sticky").css("margin-bottom", "0");
                });

                $("#tweeter-feed .tweet-message").each(function (i, message) {
                    var self = $(message);
                    self.html(linkify(self.html()));
                });

                $(".partner").on("mouseenter mouseleave", function() {
                    $(this).find(".gray-scale, .colour").toggleClass("is-hidden");
                });
            });
        
    </script>

            
<div class="sign-in-popup">
	<!-- <a href="#" class="sign-in shadow">Sign in <span class="sign-in-image-active"></span></a> -->
	<a href="#" class="sign-in ${locale}">Sign In <span class="arrow-closed sign-in-arrow-padding arrow-opened"></span></a>
	<div class="sign-in-form">

            <form action="https://f1000research.com/j_spring_oauth_security_check" id="googleOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/8-1961.html"/>
                            <input id="google-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-google" name="system" type="hidden" value="GOOGLE"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="facebookOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/8-1961.html"/>
                            <input id="facebook-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-fb" name="system" type="hidden" value="FACEBOOK"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="orcidOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/8-1961.html"/>
                            <input id="orcid-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-orcid" name="system" type="hidden" value="ORCID"/>
    </form>
		<form id="sign-in-form" class="login-container" action="https://f1000research.com/login" method="post" name="f">
           <div id="sign-in-form-gfb-popup"></div>

                                                            <input class="target-field" type="hidden" name="target" value="/articles/8-1961.html"/>
                            			<input type="text" name="username" id="signin-email-box" class="sign-in-input" placeholder="Email address" autocomplete="email">
			<input type="password" name="password" id="signin-password-box" class="sign-in-input" placeholder="Password" autocomplete="current-password">
			<div class="sign-in-remember">
                <div class="checkbox-wrapper">
    				<input type="checkbox" id="remember-me" name="remember_me" class="checkbox is-hidden">
                </div>
                <span class="checkbox-label">Remember me</span>
			</div>
			<a href="#" class="sign-in-link" id="forgot-password-link">Forgotten your password?</a>
			<div class="sign-in-button-container margin-top margin-left-20 margin-bottom">
				<button type="submit" id="sign-in-button" class="sign-in-buttons general-white-orange-button">Sign In</button>
				<button type="button" id="sign-in-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
				<div class="clearfix"></div>
			</div>
			<div class="sign-in-error">Email or password not correct. Please try again</div>
			<div class="sign-in-loading">Please wait...</div>
		</form>
		<div class="forgot-password-container">
			
<script type="text/javascript">
	$(function(){
		// Note: All the setup needs to run against a name attribute and *not* the id due the clonish
		// nature of facebox...
		$("a[id=googleSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("GOOGLE");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=facebookSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("FACEBOOK");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=orcidSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("ORCID");
            $("form[id=oAuthForm]").submit();
        });
	});
</script>

<span class="text first">
	If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.
    <p>The email address should be the one you originally registered with F1000.</p>
</span>
<input name="email" class="sign-in-input" id="email-forgot-password" type="text" placeholder="Email address">
<div class="forgot-password-email-error">
	Email address not valid, please try again
</div>
<div class="forgot-password-google-email-error">
    <p>You registered with F1000 via Google, so we cannot reset your password.</p>
	<p>To sign in, please click <a href="#" id="googleSignInButton">here</a>.</p>
    <p>If you still need help with your Google account password, please click <a href="https://www.google.com/accounts/recovery">here</a>.</p>
</div>
<div class="forgot-password-facebook-email-error">
    <p>You registered with F1000 via Facebook, so we cannot reset your password.</p>
    <p>To sign in, please click <a href="#" id="facebookSignInButton">here</a>.</p>
	<p>If you still need help with your Facebook account password, please click <a href="https://www.facebook.com/recover/initiate">here</a>.</p>
</div>
<div class="clearfix"></div>
<div class="forgot-password-captcha-error">
	Code not correct, please try again
</div>
<div class="clearfix"></div>
<div class="sign-in-button-container margin-left-20 margin-bottom">
	<button type="button" id="sign-in-reset-password" class="sign-in-buttons general-white-orange-button">Reset password</button>
	<button type="button" id="forgot-password-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
	<div class="clearfix"></div>
</div>
<span class="text last">
	<a href="mailto:">Email us</a> for further assistance.
</span>
<form action="https://f1000research.com/j_spring_oauth_security_check" id="oAuthForm" method="post" target="_top">
                        <input class="target-field" type="hidden" name="target" value="/articles/8-1961.html"/>
                <input id="oAuthSystem" name="system" type="hidden"/>
</form>
			<div class="forgot-password-server-error">Server error, please try again.</div>
			<div class="sign-in-success">
                <p>We have sent an email to <span id="email-value"></span>, please follow the instructions to reset your password.</p>
                <p>If you don't receive this email, please check your spam filters and/or contact .</p>
            </div>
			<div class="sign-in-loading">Please wait...</div>
		</div>

		<div class="sign-in-form-register-section">
			<div class="sign-in-button-container margin-left-20 margin-bottom">
				<a href="/register" title="Register"><button type="button" id="sign-in-register-button" class="sign-in-buttons general-white-orange-button">Register</button></a>
				<div class="clearfix"></div>
			</div>
		</div>

	</div>
</div>

<script type="text/javascript">
$(document).ready(function () {

    signIn.createSignInAsRow($("#sign-in-form-gfb-popup"));

    $(".target-field").each(function () {
        var uris = $(this).val().split("/");
        if (uris.pop() === "login") {
        	$(this).val(uris.toString().replace(",","/"));
        }
    });
});
</script>
        <div id="templateOverlay" class="is-hidden" hidden="hidden">
  <div class="o-overlay js-overlay is-hidden" hidden="hidden"></div>
</div>

<div id="templateExternalMessages" class="is-hidden" hidden="hidden">
  <div class="o-modal o-modal--auto@md js-external-messages is-hidden" hidden="hidden">
    <div class="o-modal__body">
      <section class="c-console">
        <div class="_mdl-layout c-console__bdy js-external-messages-body"></div>
        <footer class="_mdl-layout c-console__ftr o-flex o-flex--reverse js-external-messages-footer">
          <button type="button" class="mdl-button mdl-js-button mdl-button--raised mdl-button--colored c-console__btn js-external-messages-close" data-action="maintenance-close">I Understand</button>
        </footer>
      </section>
    </div>
  </div>
</div>

<script src="https://cdnjs.cloudflare.com/ajax/libs/moment.js/2.22.1/moment.min.js"></script>

<script src="/js/namespace.js"></script>
<script src="/js/constants.js"></script>
<script src="/js/utilities.js"></script>

<script>
                  F1000.ExtenalMaintenanceItems = [
    {
      start: '2018-12-10T14:21:00Z',
      end: '2018-12-13T16:00:00Z',
      msg: 'This site will be down for a short time on XX December. It is advisable not to start any submissions on that day or you may lose your work unless you save regularly.',
      cookieName: 'outage23122018',
      editor: false,
    }
  ];
</script>

<script src="/js/shared_scripts/cookie-helper.js"></script>
<script src="/js/shared_scripts/mdl-helper.js"></script>

<script src="/js/app/external-maintenance.js"></script>

                <script type="text/javascript">
            (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
            (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
            m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
            })(window,document,'script','//www.google-analytics.com/analytics.js','ga');

            ga('create', 'UA-5646075-11', 'auto');
            ga('require', 'displayfeatures');
            ga('send', 'pageview');
        </script>
        
                <script type="text/javascript" src="/js/app/research.analytics.js"></script>

        <!-- Start of HubSpot Embed Code -->
        <script type="text/javascript" id="hs-script-loader" async defer src="//js.hs-scripts.com/4475190.js"></script>
        <!-- End of HubSpot Embed Code -->
    
            <script src="https://my.hellobar.com/4e0495c6f18cbd68731a1dc1978195a144e767ba.js" type="text/javascript" charset="utf-8" async="async"></script>
    </body>

</html>